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Chapter 1
General Introduction
Adapted from: Acromegaly, a handbook of history, current therapy and future prospects 
Chapter 12, 2009; BioScientifica, Bristol & 
Nature Reviews Endocrinology. 2009 Oct;5(10):546-52
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Introduction 9
Introduction
HISTorIC overvIew
Giants and Acromegalics fascinated people, since ancient times. Historical artifacts, 
paintings, illustrations, photographs or articles have documented many. The earliest 
medical reports date back to 1516 [1]. In 1864 Verga was the first to describe an acro-
megalic in medical literature and called it “prosopectasia” [2]. However the article did 
not really characterize the disease. Pierre Marie was the first to do so and describe the 
disease and gave it the final name “acromegalie”, in 1886 [3]. Although Pierre Marie was 
aware of the enlarged pituitary gland he did not describe this as cause of the disease. 
In 1887 Minkowski was the first to suggest a pituitary origin of acromegaly [4]. Later 
Massalongo also described the pituitary origin and additional the relationship between 
acromegaly and Gigantism [5]. So at the end of the 19th century the disease and origin 
were unraveled. A decade later Harvey Cushing was the first to observe partial reversal 
of clinical symptoms after partial hypophysectomy, and the first form of effective treat-
ment was born [6].
Treatment
Surgery
Surgery was the first treatment option for acromegaly and gigantism. A decade before 
Harvey Cushing observed the partial reversal of clinical symptoms after partial hypophy-
sectomy, Paul and Caton performed a subtemporal decompression in an acromegaly 
patient [7]. Most operations at that time were transcranial. However Stumme and Ho-
chenegg were the first to operated trough transsphenoidal route [8]. Initial Harvey Cush-
ing adopted their transsphenoidal approach, but converted later back to the craniotomy 
and so did the majority of neurosurgeons. In the 1960’s craniotomy was perfected when 
microsurgical techniques were introduced and was the treatment of choice. It was not 
before the 20th century, that microsurgical techniques and transsphenoidal approach 
were combined and became common practice. This technique and approach were later 
perfected into a minimal invasive endoscopic method.
radiotherapy
In Paris radiation therapy for pituitary tumors started in 1907 [9]. Application of radium 
sources planted in the sphenoid sinus was applied by the early neurosurgeons. More 
focused methods of pituitary radiotherapy were developed in the late 20th century.
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Medical treatment
In the 1970’s the first of a series medical therapies were discovered. Bromocriptine, a 
dopamine agonist, normalized growth hormone (GH) and insulin-like growth factor 1 
(IGF1) in < 20 % of the patients [10-11]. Carbergoline, a more recently developed dopa-
mine agonist, was able to achieve normalization of GH and IGF1 in < 30 % of the patients 
[11-12]. In the 1980’s endogenous somatostatin was identified by, a Nobel Prize winner, 
Guillemin. Somatostatin was described as a hypothalamic peptide, which inhibited 
GH secretion of the pituitary [13]. The half-life in serum of endogenous somatostatin 
is 1-3 minutes. Octreotide, a somatostatin analog (SRIF), has a half-life of 1.5 hours and 
a 20 fold higher potency to suppress GH secretion than somatostatin [14]. Therefore 
octreotide had to be administered 3 times a day. To date the regular octreotide is rarely 
used. Depot formulations with microspheres (octreotide LAR) or the water solution 
(Lanreotide Autogel) facilitates the use of somatostatin analogs and increased efficacy 
[15-16]. Long-acting SRIF analogs have efficacy rates of about 50 % in normalizing GH 
and IGF1 [17]. A decade later a new class of antagonist, where developed named Pegvi-
somant [11,18]. Pegvisomant (PEG-V), a growth hormone receptor antagonist, is to date 
the most effective therapy for acromegaly.
TreATMeNT ModAlITIeS To dATe
Surgery
Over 90 % of the patients that are treated by surgery are treated using a transsphenoidal 
approach. Transsphenoidal surgery is well-established first line treatment for microad-
enomas in acromegaly. In patients with a microadenoma, remission can be achieved in 
about 80% [17] and recurrence is reported in 3-10% of the patients [19-22]. Long-term 
efficacy largely depends on the experience of the neurosurgeon, while GH levels at 
diagnosis, tumor size and extrasellar invasion also play a major role in this. When e.g. 
in hospitals without highly specialized neurosurgeons, remission rates in patients with 
microadenomas of less than 40 % are not uncommon [23]. Compared to SRIF analogs 
with an efficacy rate of 44-77% in normalizing IGF1 levels, remission rates for surgery of 
40%-80%, are within the same range. However, successful surgery is accompanied by 
a rapid fall in GH and IGF1 and the costs are relative low when compared to long-term 
drug therapy (SRIF analogs, PEG-V).
However, after surgery in less than 50 % of patients with macroadenomas remission is 
reached, even in experienced neurosurgical centers [24]. Generally, reported remission 
rates are between 20-30 % for macroadenomas [23]. When compared to efficacy rates 
of medical treatment with SRIF analog and/or PEG-V, surgical efficacy rates in patients 
with macroadenomas are unacceptably low. There might be one exception, which is 
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the intrasellar macroadenoma. In this specific case remission rates are observed of ap-
proximately the same magnitude as with the microadenomas [23].
radiotherapy
Conventional radiotherapy (RT) has been used as adjuvant treatment in acromegaly for 
many years and is still used for that purpose to date. Conventional RT is delivered in 
fractionated doses over a period of 5 to 6 weeks. The total amount administered is gen-
erally 40-50 Gray, at the level of the pituitary adenoma. With conventional RT remission 
rate of 50-60% after a mean follow up of 10 years are common [25-26]. The efficacy rates 
depend on the baseline GH and IGF1 levels more, as in most other treatment strategies. 
GH levels decrease to about 50% of their initials values within the first 2 years, and after 
that, a gradual further decrease in the next two decades can be expected. Within the first 
year after RT, control of tumor size can be achieved already and in more than 50% of the 
cases some decrease is tumor size is observed.
Post-radiotherapy hypopituitarism is reported in 50-80% of subjects after a mean fol-
low up of 10 years [25-27].
Medical treatment
Somatotroph adenomas predominately express somatostatin sub-type 2 receptor 
(SSTR2) and SSTR5 [15]. The two commercially available long-acting SRIF analogs, 
octreotide LAR and lanreotide autosolution, predominately bind to the SSTR2, with 
similar affinity [15]. Octreotide LAR and lanreotide autosolution are SRIF analogs that 
inhibits GH secretion of the pituitary. Both formulations have more or less the same 
efficacy rates [15]. Normalisation of IGF1 and GH (< 2.5 μg/l) are observed in about 50 % 
of the patients, for both adjuvant and primary medical therapy [17]. The efficacy rates 
of somatostatin might be increased by gross debulking of the macroadenoma as was 
reported by e.g. Petrossians and co-workers [28]. The studies that have been conducted 
on the long-term treatment with SRIF analogs included patients who where responsive 
to SRIF analogs before start of the study [24] which is a clear bias.
In one of the few available prospective studies, SRIF analogs reduced sign and 
symptoms and induce tumour shrinkage in about 42 % of the patients [29]. In theory, 
pre-operative tumour shrinkage might improve surgical efficacy rates. Recently, a 
randomized controlled trial indeed observed improved normalization rate of IGF1, but 
not of GH, in patients with macroadenomas, who were pre-treated for 6 months with 
octreotide LAR [30]. The efficacy rates of PEG-V are much higher than for SRIF analog, but 
it has to be administrated by a subcutaneous injection daily and yearly cost are at least 
twice as high as for SRIF analogs. After long-term treatment with PEG-V, high efficacy in 
normalising IGF1 levels in more than 90 % of patients has been reported [31].
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PEG-V is a recombinant growth-hormone analog with a Gly120Arg substitution in 
growth-hormone binding site 2 and eight amino acid substitutions in growth-hormone 
binding site 1, which result in the lack of functional growth hormone receptor signaling 
and an enhanced affinity for the growth hormone receptor (Figure 1) [11]. Owing to its 
pegylation (that is, covalent attachment of polyethylene glycol polymer chains), pegvi-
somant is a stable, 42–46 kD molecule with decreased immunogenicity and prolonged 
half-life [18,32].
AIMS of TreATMeNT
The aims of long-term treatment should be morbidity and especially mortality rates are 
the most important parameters. Mortality rates have been assessed for RT and pituitary 
surgery. However, no data is available on (primary) medical treatment, yet. However 
reduction in mortality can be achieved by any effective therapy that normalizes GH 
and IGF1. Medical treatment modalities are effective therapies therefore it might be 
expected that in the future data will be available on possible reduction of mortality and 
morbidity. The most important biochemical predictors of mortality in acromegaly are 
GH [33-35] and IGF1 [19,36-37]. There is some evidence that the latest GH could be a 
more important predictor of increased mortality risk than the latest IGF1 [38].
figure 1: Ligand binding to the growth-hormone receptor. a | A schematic diagram of growth hormone 
binding to the dimerized growth-hormone receptor, which results in a conformational change of 
the membrane-bound receptor and activation of the downstream signal-transduction pathway. b | 
Pegvisomant binding to the dimerized growth-hormone receptor. Binding site 1 of pegvisomant contains 
eight amino acid substitutions that improve binding of this molecule to the receptor. Binding site 2 
contains a single amino-acid substitution (Gly120Arg) that blocks the conformational change of the 
growth-hormone receptor and thereby inhibits downstream signal transduction.
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There is an ongoing discussion in literature on what normal GH and IGF1 levels are. 
Some studies use a single GH of less than 2.5 μg/liter [19]. The consensus guideline 
states that mean of a 24-hr GH profile should be to less than 2.5 μg/liter or a GH nadir 
of less than 1.0 μg/liter and an IGF1 level into the age adjusted normal limits [39]. How-
ever, using these criteria, Dekkers and co-workers demonstrated that in that case, the 
standardized mortality rate (SMR) is still increased to 1.3 [40]. The SMR from this meta-
analysis is mainly based upon studies conducted in acromegalic patients treated with 
transsphenoidal surgery. The current effective medical treatment strategies, as PEG-V 
and/or SRIF analog were not incorporated in this meta-analysis. With these effective 
medical therapies, it might be expected that mortality rate will indeed completely nor-
malize. Furthermore, most reports on mortality rates in acromegaly used GH values that 
were assessed by a competitive, less sensitive, RIA. Nowadays, GH is assessed by sensi-
tive sandwich immunoassays. Therefore, it is hard to predict how ‘old’ GH levels must be 
translated into ’modern’ GH concentrations, assessed by modern assays. The evolution 
in GH assays does influence the discussion about what level GH should be regarded 
as safe. The optimal GH nadir is probably below 1.0 μg/l but the optimal threshold in 
not defined yet. Some authors suggest 0.5 µg/l [41] while others mention 0.4 μg/l [42]. 
The use of a too high cut-off level for GH as the target level probably explains why the 
SMR was elevated in the meta-analysis of Dekkers et al. In the recent New Zealand 
meta-analysis, mortality appeared not to be increased when random GH were <1.0 μg/l, 
assessed by a sensitive essay [43]. One potential draw-back of using lower target levels 
for GH together with the availability of effective medical treatment is that it can lead to 
overtreatment in acromegaly patients.
Quality of life in acromegalic patients
Since it has become possible to normalize biochemical markers in virtually all acrome-
galic patients, one should endeavor for a new objective. From a patients perspective 
quality of life (QoL) may be the most important parameter of her or his disease. As previ-
ously mentioned, by lowering GH and IGF1 morbidity decreases. Morbidity is part of the 
QoL, but does not cover the whole concept.
RT decreases the QoL especially joint complaints [37]. Over time this decreased QoL 
seems even to deteriorate after RT [44]. Improvement in QoL of acromegalic patients will 
most likely be a topic of increased interest within the next decade.
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(PATHo)PHySIology
Hypothalamic hormones GH-releasing hormone (GHRH), SRIF analog through the 
pituitary portal system regulate the pulsatile GH secretion of the anterior pituitary so-
matotroph cells [45]. Another GH releasing hormone is Ghrelin a gut-derived hormone 
[46]. Ghrelin acts mainly at hypothalamic level as a GH secretagogue in synergy with 
GHRH. It acts through the ghrelin secretagogue receptor type Ia (GHS-RIa). These three 
are the main regulator of GH. GHRH and ghrelin stimulated whereas SRIF analog inhibits 
GH secretion [46-48]. GH stimulates the IGF1 production in the liver and peripheral tis-
sues [49]. To stabilize IGF1 serum levels, it binds to IGF1 binding protein 3 (IGF1BP3) and 
acid-labile-subunit (ALS). GH is the main regulator of both IGF1BP3 and ALS. Vice versa 
IGF1 regulates GH by a negative feedback (Figure 2) [11].
GH is not just a releasing factor for IGF1. In contrast to IGF1, GH has lipolytic and hy-
perglycemic, as IGF1 has glucose lowering effect. So GH and IGF1 have partly synergistic 
and antagonistic actions.
figure 2: Physiology of the GH secretion by the pituitary.
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AIMS ANd ouTlINe of THIS THeSIS
The general aim of the research presented in this thesis is to assess the (long-term) ef-
ficacy, safety, and cost reduction of combined treatment with somatostatin analogs and 
a GH receptor antagonist and the tissue specific physiology of the GH/IGF1.
The first part, chapter 2, 3 and 4, of this thesis focuses on the efficacy, safety and costs 
of combination treatment in previously uncontrolled acromegaly patients. The second 
part, chapter 5 and 7, will emphasize on QoL in long-term controlled acromegaly 
patients during long-acting SRIF analog, with or without PEG-V and the tissue specific 
physiology of the GH/IGF1.
In chapter 6 more physiology of GH is study but at a pituitary level. We studied if an 
ultrashort feedbackloop for GH on the pituitary is the explanation for the raise in GH 
serum levels during PEG-V treatment.
Chapter 8 discusses the benefits and side effects of combination treatment and looks 
to the future of acromegaly treatment and possible changes in the way we treat acro-
megaly to date.
Finally, chapter 8 covers the general discussion and conclusion.
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AbSTrACT
Background: We previously reported the efficacy of a combined treatment of active ac-
romegaly with both long-acting somatostatin analogs (SRIF) and pegvisomant (PEG-V).
Objective: Our objective was to assess long-term efficacy and safety in a larger group of 
acromegalic patients after a period of 138 (35–149) wks [median (range)].
Design: PEG-V was added to high-dose SRIF analogs treatment in 32 subjects (13 fe-
males) who had not shown a normalization in serum IGF1 concentrations during SRIF 
analog monotherapy. PEG-V dosage was increased until IGF1 concentration normalized. 
The maximal dose was 80 mg twice weekly.
Results: After dose finding, IGF1 remained within the normal range in all subjects with 
PEG-V administered once (n = 24) or twice (n = 8) weekly, on a total weekly dose of 60 
(40–160) mg. Baseline IGF1 levels were positively correlated with the required dosage of 
PEG-V (r = 0.48; P = 0.006). PEG-V-dependent liver enzyme disturbances were observed 
in 11 (6 diabetic) subjects, of which symptomatic gallstones explained two cases. These 
liver enzyme disturbances were transient in all subjects without discontinuation or 
dose adaptation of PEG-V. In our series, diabetic patients had a 5.1 times (odds ratio) 
(confidence interval, 1.02–25.54; P < 0.05) higher risk for developing liver enzyme distur-
bances. These liver enzyme disturbances seemed to occur earlier. Pituitary adenoma size 
decreased in four patients. No increase in tumor size was observed in any of the patients.
Conclusion: Long-term combined treatment with long-acting SRIF analogs and (twice) 
weekly PEG-V for active acromegaly seems to be effective and safe. Patients with acro-
megaly and diabetes seem to have a higher risk of developing transient liver enzyme 
disturbances.
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INTroduCTIoN
The clinical management of acromegaly has changed recently because optimal therapy 
has proven to reverse the increased mortality associated with acromegaly. Currently, 
transsphenoidal surgery (TSS) is still the treatment of choice for acromegaly, although in 
only 60% is an adequate biochemical remission or cure achieved. A chance on remission 
declines to less than 50% if a macroadenoma is present [1]. Radiotherapy (RT), primary 
or postsurgically, is limited due to slow onset of effect and has a high occurrence of pan-
hypopituitarism [2-4] and decreased quality of life [5]. Nowadays, medical therapy plays 
an important role in controlling signs and symptoms of acromegaly, both as primary 
and secondary medical therapy. Long-acting somatostatin analogs (SRIF) normalize 
IGF1 levels in two thirds of patients with acromegaly [6-11]. One of its side effects is the 
suppression of insulin secretion, which could lead to glucose intolerance [12-13].
A more recent medical treatment modality is the GH receptor antagonist pegviso-
mant (PEG-V). With daily injections of PEG-V, in more than 90% of patients a normal-
ization of IGF1 can be achieved [14-15]. In addition, glucose metabolism is improved 
[16-17,13,18,15]. On the other hand, PEG-V has to be administered daily, and in some 
patients it was at least unable to prevent tumor growth [19]. Combination of SRIF analog 
and PEG-V treatment seems to be an attractive option because tumor suppression is 
combined with GH receptor blockade. We previously reported that PEG-V, administered 
weekly in addition to long-acting SRIF analog therapy was able to normalize serum IGF1 
levels in 95% of subjects [20]. Here we present the long-term follow-up efficacy and 
safety data in the same patients plus newly included acromegalic subjects up to 138 
(35–149) wks [median (range)].
PATIeNTS ANd MeTHodS
Patients
Patients were enrolled from a single center. All subjects [n = 32, 13 females; median age 
52 (range 30–81) yrs] had elevated IGF1 levels [56 (32–122) nmol/liter] despite 120 mg 
lanreotide Autogel (n = 22) or 30 mg octreotide LAR (10) monthly for at least 6 months 
before the start of this series. Baseline characteristics are presented in Table 1. In our 
series, patients with a pituitary macroadenoma and compression of the chiasm were not 
treated with a combination of SRIF analog and PEG-V.
Methods
All patients continued long-acting SRIF analog therapy at monthly intervals and, on 
top of that, PEG-V was added weekly. Starting dose of PEG-V was 40 mg weekly. PEG-V 
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dosage was adjusted until IGF1 was within the age-adjusted normal range. If IGF1 fell 
in the lowest quartile of normal, the PEG-V dosage was reduced. The intervals of dose 
adjustments were 6 wks until a controlled IGF1 was achieved twice. The subjects then 
visited our outpatient clinic every 12–16 wks. If a dose of at least 100 mg was required, 
patients divided the dosage in two (equal) parts and injected twice weekly.
IGF1 and other efficacy and safety data were assessed at these regular visits. Efficacy 
was assessed at the longest follow-up visit [138 (35–149) wks] for IGF1, GH, glycosylated 
Table 1. Baseline characteristics (n=32)
n (%)1
Patients 32 (100)
Sex (female) 13 (41)
Age (yrs), mean (SD,range) 53 (12.8,30-81)
dM 11 (34)
Igf1 at nmol/liter baseline
 Mean (SD) 65.0 (28.9)
 Median (range) 60.0 (32.0–122.0)
 1–2 x ULN 18 (56)
 2–3 x ULN 9 (19)
 >3 x ULN 5 (16)
gH (µg/liter) at baseline
 Mean (SD) 10 (14.2)
 Median (range) 5.2 (0.4-69.8)
Previous treatment
 Both TSS and RT 8 (25)
 TSS 6 (19)
 Primary medical therapy 18 (56)
duration of long-acting SrIf before combination (wks)
 Mean (SD) 114 (82.7)
 Median (range) 79.3 (33.1-320.0)
Pituitary insufficiency
 Pan-hypopituitarism 9 (28)
 1–2 axis 13 (41)
 No hypopituitarism 10 (31)
long-acting SrIf analogs
 Lanreotide 22 (69)
 Octreotide 10 (31)
DM, diabetes mellitus; RT, radiotherapy; SRIF, somatostatin; TSS, transsphenoidal surgery; wks, weeks; x 
ULN, Times upper limit of normal.
1 Unless otherwise specified.
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hemoglobin (HbA1c), fasting glucose, lipids, and a quality of life questionnaire, Patient-
Assessed Acromegaly Symptom Questionnaire [14]. IGF1 and GH concentrations were 
measured by immunometric assays (Diagnostic Products Corp., Los Angeles, CA). The 
IGF1 age-adjusted reference ranges were used [21].
Safety assessment included electrocardiogram, serum concentrations of alkaline 
phosphatase, γ-glutamyltranspeptidase (γ-GT), alanine aminotransferase (ALT), aspar-
tate aminotransaminase (AST), lactate dehydrogenase, total bilirubin, and change in 
pituitary tumor volume. Tumor volume was assessed at baseline by magnetic resonance 
imaging, which was repeated every 6 months. Changes in pituitary tumor size were as-
sessed by the same neuroradiologist.
Statistical analysis
Paired nonparametric data were analyzed with the Wilcoxon’s signed-rank test. The 
non-paired data were assessed with the Mann- Whitney U test and cross-tables with the 
Fisher’s exact test. Statistical analyses of the data were performed by Prism version 5.00 
for Windows (GraphPad Software, San Diego CA). Statistical significance was accepted 
at P < 0.05 (two-tailed). Data are expressed as median ± SD unless otherwise specified.
reSulTS
efficacy
Thirty-two patients with acromegaly were enrolled in this series. Normalization of serum 
IGF1 levels was achieved in all patients (Figure 1). The median IGF1 decreased from 56.00 
± 28.7 nmol/liter at baseline, on SRIF analogs monotherapy, to a lowest level of 17.85 
± 6.16 nmol/liter (P < 0.0001) during combined treatment. The PEG-V dose needed for 
normalization of IGF1 was 60 (40–160) mg weekly [median (range)]. This median dose 
is identical to the one we reported previously [20]. Eight patients needed PEG-V twice 
weekly.
The necessary dose of PEG-V for normalization of IGF1 was not significantly different 
in the primary medical therapy group (60.00 ± 43.27 mg) vs. the TSS group (55.00 ± 40.08 
mg). A similar observation was made with regard to the diabetes mellitus (DM) group 
(55.00 ± 58.27 mg) vs. non-DM group (60.00 ± 32.70 mg). The necessary dose of PEG-V 
for normalization of IGF1 was positively correlated with baseline IGF1 levels, corrected 
for age (r = 0.48; P = 0.006) (Fig. 2).
Metabolic control in patients with DM improved significantly after normalization of 
IGF1 during combined treatment. Nine of 10 DM patients had a significant decrease in 
HbA1c (P = 0.0156). Even after normalization of IGF1, and with the same PEG-V dose, a 
further significant decrease in HbA1c could be observed (P = 0.0313) over a period of 
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6–18 months. In one patient, HbA1c could not be assessed because of hemoglobinopa-
thy. Patients on insulin therapy (n = 7) had to decrease their insulin dosage, and one 
patient could stop insulin therapy and continued oral medication for DM. The remaining 
three patients did not change their insulin dosage, but still their HbA1c levels decreased.
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figure 1: IGF1 concentration in serum of 31 patients with acromegaly , before (●) and after (○) 138 
(35-149) weeks of combined therapy.
Shaded area indicates age-dependent normal range for IGF1.
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figure 2: The relation between baseline IGF1 and the necessary dose of pegvisomant (PEG-V) in a linear 
regression model. IGF1 is corrected for age by Z-score. r =0.48; p=0.006.
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Quality of life, compared with baseline, was improved in any assessment during 
follow-up (P < 0.05). IGF1 correlated well with quality of life.
Safety
Transient elevated liver enzyme tests (TLET) were observed in 11 patients (34%) (Table 
2). Of these 11 subjects with TLET, six patients (55%) also suffered from DM. In our study, 
acromegaly patients with DM had a 5.1 times (odds ratio) (confidence interval, 1.02–
25.54; P < 0.05) higher risk for developing TLET than nondiabetic subjects. We already 
reported on one diabetic patient who developed a transient drug-induced hepatitis due 
to which pegvisomant medication was stopped after 25 wks [22].
Table 2. Clinical and biochemical characteristics of 11 patients with liver enzyme disturbances during 
combined therapy of SRIF analogs and PEG-V (twice) weekly
Sex Age
(yrs)
Time between 
start of Peg-v 
and lfT
(weeks)
weekly 
Peg-v dose at 
onset of lfT 
elevations
Peak lfT
AlT AST γgT
----(xulN)----
dM follow up
In all patients Peg-v was 
continued
M 61 24 60 3.0 1.8 1.5 + LFT normalized < 12 weeks
M 38 20 60 1.8 1.3 1.1 - LFT normalized < 18 weeks
F 66 12 40 2.0 1.2 2.0 + LFT normalized < 18 weeks
M 48 46 160 2.4 1.1 1.2 + LFT normalized < 18 weeks
M 61 24 60 3.0 1.8 1.5 + LFT normalized < 12 weeks
F 57 24 60 5.1 2.6 3.0 - LFT normalized < 12 weeks
M 53 17 60 31.6 14.2 18.4 + MRCP showed gallstones, LFT 
declined rapidly and normalized 
< 8 weeks
M 30 86 60 8.8 4.7 5.7 - Bile duct obstruction. LFT 
normalized
after cholecystectomy < 1 week
M 44 48 60 4.8 2.9 5.1 - LFT normalized < 18 weeks
F 45 92 40 2.3 1.2 1.0 - LFT normalized < 3 weeks
M 47 25 60 31.9 7.1 7.6 + PEG-V withdrawn, LFT normalized
M 62 18 40 2.8 2.0 10.4 + LFT normalized < 12 weeks
M 38 20 60 1.8 1.3 1.1 - LFT normalized < 18 weeks
M 48 46 160 2.4 1.1 1.2 + LFT normalized < 18 weeks
M 61 24 60 3.0 1.8 1.5 + LFT normalized < 12 weeks
M 44 48 60 4.8 2.9 5.1 - LFT normalized < 18 weeks
M 30 50 200 1.5 0.4 0.8 + LFT normalized < 6 weeks
M 46 8 80 4.3 3.3 2.2 - LFT normalized < 12 weeks
M 47 25 60 31.9 7.1 7.6 + PEG-V withdrawn, LFT normalized
F, Female; M, male; LFT, liver function tests; xULN, times upper limit of normal; DM, diabetes mellitus; 
MRCP=Magnetic resonance cholangiopancreatography.
Sebastian BW.indd   27 18-Apr-11   15:48:49 PM
28 Chapter 2
Data of this patient are included in the safety data and baseline analyses. Subjects with 
DM also tended to have an earlier onset of TLET (21.0 ± 10.5 wks) than subjects without 
(25.0 ± 36.3 wks), although this was not significant (P = 0.178) (Fig. 3). The duration of 
the TLET was the same in both DM (12.0 ± 6.1 wks) and non-DM (18.0 ± 11.5 wks). In 
two patients, gallstones, possibly related to long-term use of SRIF analogs, could explain 
the TLET. Patient 8 (Table 2) was diagnosed as having cholecystitis and underwent cho-
lecystectomy, after which TLET normalized rapidly. In patient 7, a magnetic resonance 
imaging scan of the liver revealed gallstones, and the TLET spontaneously disappeared 
without intervention. We concluded that in this patient, passage of a gallstone caused 
the TLET.
In 28 subjects, no increase in size of the pituitary tumor was observed. In four subjects 
(13%), a regression in tumor size by more than 25% occurred. None of these four patients 
had received RT before enrollment in this series, whereas three subjects (9%) were on 
primary medical therapy and had been treated for 43, 45, and 73 wks with monotherapy 
SRIF analogs and for 74, 148, and 143 wks with combination therapy. The other subject 
had TSS 2 yr before enrollment and had been treated for 71 wks with monotherapy SRIF 
analog and 143 wks with combination therapy.
dISCuSSIoN
We report here that long-term combined therapy of acromegalic patients with long-
acting SRIF analogs and PEG-V (twice) weekly is highly effective and safe. In all patients, 
IGF1 could be brought back within the age-adjusted reference range. Compared with 
the reported remission rates of long-acting SRIF analogs of about two thirds of patients, 
figure 3: The interval between start of therapy and onset of transaminases abnormalities divided in 
acromegaly patients with (+) and without (-) DM. The individual subjects are shown as closed circles, and 
the line represents the median.
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the combination therapy seems superior. It is comparable with the efficacy of PEG-V 
daily administrations as monotherapy for acromegaly, which is considered to be more 
than 90% [14-15]. We observed that the (twice) weekly dose of PEG-V that is necessary 
for IGF1 normalization is equal to the one, we reported earlier (median, 60 mg; range, 
40–160 mg) [20]. Probably mainly because of the reduced levels of endogenous GH due 
to the SRIF analog therapy, less PEG-V is needed to normalize serum IGF1 levels, because 
it meets less GH to compete for GH receptor binding. The necessary dose of PEG-V for 
normalization of IGF1 was associated with baseline IGF1 levels on monotherapy SRIF 
analogs. In previous studies with PEG-V monotherapy, such a relationship was not ob-
served. The dose of PEG-V necessary for normalization of IGF1 did not differ between pa-
tients with primary medically treated patients and patients who previously underwent 
TSS (with or without RT). This is in contrast to studies on SRIF analogs monotherapy, 
showing that previous tumor debulking leads to a higher percentage of patients achiev-
ing biochemical remission with SRIF analogs [23].
In 11 patients (34%), we observed TLET. Two patients had TLET due to gallstones 
probably related to the use of long-acting SRIF analogs [20]. Liver enzyme disturbances 
during daily PEG-V treatment, AST, and ALT are usually more elevated than γ-GT and 
bilirubin [24]. The more prominent elevation in γ-GT and bilirubin led to the conclu-
sion that in two patients, the TLET was caused by cholelithiasis. The majority of patients 
who developed TLET had DM. These patients have an odds ratio of 5.1 to develop TLET 
during combination treatment and also tended to develop TLET earlier compared with 
patients without DM, although this was not significant. Another study assessed TLET in 
12 patients with daily PEG-V of whom two subjects were cotreated with monthly long-
acting octreotide (30 mg) [24]. The liver enzyme disturbances were not dose related and 
occurred after 15.7 ± 10.7 wks (mean ± SD). However, no association of a phenotypic 
predictor was found. The mechanism of PEG-V-induced TLET remains unclear. The reason 
why the DM acromegalic patients in our series develop TLET earlier and more frequently 
also remains the subject of conjecture. We could not find another predictor that could 
explain the TLET. Although in our patients we did observe elevated liver enzyme tests, 
we consider the combined treatment as a safe treatment option of acromegalic patients 
that do not respond enough to monotherapy with SRIF analogs, because these mild dis-
turbances of liver enzymes are transient without discontinuation or dose adaptation of 
PEG-V. This is in contrast to some other studies in which PEG-V is withdrawn. A frequent 
assessment of liver enzymes, as already indicated by the package insert of PEG-V, seems 
mandatory, however, especially in patients with DM.
In our series, we did not observe tumor growth in any of the patients. Four subjects 
even showed a regression in tumor size by more than 25%. It is noteworthy that none of 
these subjects were previously treated with RT.
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From our clinical experience, one starts with a weekly dose of 40 mg PEG-V, which can 
be increased by 20 mg every 6 wks until normalization of IGF1 has been achieved. In our 
hands, we need two to three steps of dose titration to normalize IGF1 in the majority of 
patients, achieving disease control within 3 months after starting combination therapy.
In conclusion, although more research is necessary in larger cohorts of patients, our 
series indicates that long-term combined treatment of active acromegaly with both 
long-acting SRIF analogs and (twice) weekly injections of PEG-V seems to be effective 
and safe, at least for those subjects in whom serum IGF1 remains elevated during SRIF 
analogs monotherapy. Transient and mild elevations in liver functions were observed in 
one third of patients, and especially diabetic patients seemed to be more prone to this 
side effect.
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AbSTrACT
Background: We previously reported on the efficacy, safety, and quality of life (QoL) of 
long-acting somatostatin analogs (SRIF) and (twice) weekly pegvisomant (PEG-V) in 
acromegaly and improvement after the addition of PEG-V to long-acting SRIF analogs.
Objective: To assess the long-term safety in a larger group of acromegalic patients over 
a larger period of time: 29.2 (1.2–57.4) months (mean (range)).
Design: Pegvisomant was added to SRIF analog monotherapy in 86 subjects (37 females), 
to normalize serum IGF1 concentrations (n=63) or to increase the QoL. The median dos-
age was 60.0 (20–200) mg weekly.
Results: After a mean treatment period of 29.2 months, 23 patients showed dose-
independent PEG-V related transient liver enzyme elevations (TLET). TLET occurred 
only once during the continuation of combination therapy, but discontinuation and 
re-challenge induced a second episode of TLET. Ten of these patients with TLEE also 
suffered from diabetes mellitus (DM). In our present series, DM had a 2.28 odds ratio 
(CI 1.16–9.22; p=0.03) higher risk for developing TLET. During the combined therapy, a 
clinical significant decrease in tumor size by more than 20% was observed in 14 patients. 
Two of these patients were previously treated by pituitary surgery, 1 with additional 
radiotherapy and all other patients received primary medical treatment.
Conclusion: Long-term combined treatment with SRIF analog and twice weekly PEG-V 
up to more than 4 years seems to be safe. Patients with both acromegaly and DM have a 
2.28 higher risk of developing TLET. Clinical significant tumor shrinkage was observed in 
14 patients during combined treatment.
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INTroduCTIoN
Recent studies of new medical treatment strategies with pegvisomant (PEG-V) for acro-
megaly have reported on high efficacy. PEG-V, alone or in combination with somatostatin 
analog (SRIF), has an efficacy of >90% to control insulin-like growth factor (IGF1) [1-4]. 
This is much higher than SRIF analogs, with an efficacy of ±66% [5]. However, PEG-V is 
at least unable to prevent tumor growth [6,4] in contrast to SRIF analogs. During SRIF 
analog treatment as primary medical therapy, pituitary tumor shrinkage was observed 
in 52% of the patients versus 21% for adjuvant therapy [7]. With combination therapy 
of SRIF analog and PEG-V twice weekly, tumor shrinkage was observed in 14% of the 
patients [2].
Side effects of SRIF analog therapy and PEG-V are elevated liver enzymes, but they 
have a different etiology. SRIF analogs increase the risk for cholelithiasis, which can cause 
cholestatic liver enzyme disturbances. PEG-V induces mainly elevated transaminases. 
The mechanism behind these PEG-V-induced elevated transaminases is unknown. A 
long-term report on daily PEG-V treatment reported elevated liver enzymes in 21 out of 
the 229 patients [6]. When PEG-V is combined with SRIF analog, there seems to be a bet-
ter control of tumor size, but transient liver enzyme elevations (TLET) seem to occur in 
about 34% of the patients and diabetic patients seem to be more prone [2]. SRIF analogs 
alone have the highest efficacy for tumor shrinkage but for the control of IGF1 they are 
less effective.
Recently, we have reported on the improved quality of life (QoL) after the addition 
of PEG-V to acromegaly patients with an IGF1 within the age-adjusted normal range 
during the long-acting SRIF analog therapy [8]. Therefore, combined therapy might be 
an attractive option for the treatment of acromegaly.
Despite these observations, the Canadian Health Authorities sent out a safety warning 
about the combination therapy on June 11, 2008, because of the development of TLEE. 
This warning was based on a post-marketing study in 26 patients, conducted by Pfizer. 
We now report the safety of combined therapy assessed in 86 acromegalic patients over 
29.2 (1.2–57.4) (mean (range)) months.
PATIeNTS ANd MeTHodS
Patients
Eighty-six acromegalic patients, 37 female, with a mean age of 54 (range 19–83) years 
were enrolled in our center, after their informed consent and approval by the local ethics 
committee. Their medical history revealed transsphenoidal surgery (TSS) in 44 subjects, 
TSS and radiotherapy in 20, while 42 subjects received primary medical treatment. 
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Twenty-one subjects also suffered from diabetes mellitus (DM). All patients were on SRIF 
analog treatment (octreotide LAR n=31, lanreotide Autogel n=55) for at least 6 months 
before PEG-V was added.
Methods
All patients continued long-acting SRIF analog therapy and on top of that, PEG-V was 
added twice weekly. Results were derived from two data sets. The first data set contains 
data from acromegalic patients (n=63) with elevated IGF1 levels at baseline. This group 
is described in this article as the ‘uncontrolled group’. The second data set of patients 
(n=23), who were titrated up with PEG-V to improve the QoL, are described as ‘QoL 
group’.
Of the uncontrolled group, 19 acromegalics started with a 25 mg, another 13 with 40 
mg, and the last 26 patients started with a variable dose of PEG-V weekly guided by their 
baseline IGF1. This variable start dose was based on our previous observation that base-
line IGF1 predicted the PEG-V dose that is necessary to control IGF1 [2]. Intervals of dose 
adjustments were 6 weeks until a controlled IGF1 was achieved twice. The subjects then 
visited our outpatient clinic every 16 weeks. The QoL group started with 20 mg PEG-V 
weekly and the dosage was adjusted on the basis of their QoL. The intervals of dose 
increments were 8 weeks until either serum IGF1 decreased below 2 S.D. or a worsening 
in QoL was observed after the initial improvement. Subjects visited our outpatient clinic 
at least every 16 weeks. The QoL was assessed by the acromegaly QoL questionnaire [9] 
and the patient-assessed acromegaly symptom questionnaire [3-4]. The dose of PEG-V 
was administered by the patients themselves. If the once weekly dose exceeded 80 mg, 
patients divided the dosage into two equal parts and injected twice weekly. At every 
visit to our outpatient clinic, safety parameters were assessed.
Safety assessment included: EKG, serum concentrations of alanine aminotransferase, 
aspartate aminotransaminase, alkaline phosphatase, γ-glutamyltranspeptidase, total 
bilirubin, and lactate dehydrogenase. Yearly, change in pituitary tumor volume was as-
sessed by magnetic resonance imaging (MRI) and by the same neuroradiologist.
Statistical analysis
The non-paired data were assessed with the Mann–Whitney test, and cross-tables and 
odds ratio with the Fischer’s exact test. Statistical analysis of the data was performed 
by GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego, CA, USA. 
Statistical significance was accepted at P<0.05. Data are expressed as mean ±S.D. unless 
otherwise specified.
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reSulTS
Safety analyses were performed in all 86 patients with a follow-up of 29.2±20.2 months 
(Figure 1) and a median dose of 60 mg (range; 20–200) mg weekly. The dose of PEG-V in 
the uncontrolled group was median 60 mg (mean, 77; range, 20–200) weekly. The dose 
in the QoL group was also 60 mg (53; 20–80) (median (mean; range) weekly.
TLEE were observed in 23 patients (23/86, 27%; Table 1). Relevant TLEE of more than 
three times the upper limit of normal (ULN) were observed in 13 patients (13/86, 15%). In 
2 out of these 13 patients, the TLEE could be explained by gallstones and 1 patient devel-
oped a transient drug-induced hepatitis, which have been reported elsewhere [10,2]. Ten 
out of 23 subjects with TLEE also suffered from DM. The odds ratio for developing TLEE 
was 2.28 (CI 1.16–9.22; p=0.03) for diabetic subjects. Six patients with TLEE 3x ULN were 
also diabetic. The risk for developing relevant TLEE for diabetics subjects was 3.31 (odds 
ratio, CI 1.00–11.37; p=0.07). TLEE occurred after 33±25 (range 8.0–92.0) weeks after 
the start of PEG-V. In diabetic acromegalic patients, TLEE were observed after 29.6±7.4 
weeks versus 34.6±30.2 weeks in non-diabetic subjects, which was not significantly 
different. The TLEE of 3x ULN in diabetics were observed after 25.3±18.0 weeks versus 
29.4±25.8 weeks in non-diabetic subjects, neither significantly different. The duration of 
the TLEE was 12.1±6.1 weeks, without a significant difference between diabetic 13.0±5.1 
weeks versus non-diabetic acromegalics 11.3±7.0 weeks. No correlation was observed 
between TLEE and PEG-V dose. In the QoL group, we observed TLEE in five subjects. Four 
of these patients were also reported to have TLEE in our prior study [8]. After re-exposure 
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figure 1: Number of subjects treated with twice weekly PEG-V and SRIF analog, divided over treatment 
periods of one, two, three, or more than 3 years.
SRIF = somatostatin, PEG-V = pegvisomant
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with PEG-V during dose finding for an optimal QoL, TLEE reoccurred in all subjects. In Fig. 
2, TLEE of two of these patients are presented, while the two other subjects had similar 
results.
Another known side effect of PEG-V treatment, at the injection site, which did not 
occur during our previous follow-up is lipohypertrophy [11]. Reversible lipohypertrophy 
was observed in three patients at the abdominal injection sites, after at least 3 months 
Table 1. Clinical and biochemical parameters of 23 patients with elevated liver enzymes during 
combination therapy.
Sex Age
(yrs)
Time between 
start of Peg-v 
and lfT
(weeks)
weekly Peg-v 
dose
at onset of lfT 
elevations
Peak lfT
AlT AST γgT
----(xulN)----
dM follow up
In all patients Peg-v was 
continued
M 53 17 60 31.6 14.2 18.4 + MRCP showed gallstones, 
LFT declined rapidly and 
normalized < 8 weeks
M 30 86 60 8.8 4.7 5.7 - Galway obstruction. 
LFT normalized after 
cholecystectomy < 1 week
M 62 18 40 2.8 2.0 10.4 + LFT normalized < 12 weeks
M 38 20 60 1.8 1.3 1.1 - LFT normalized < 18 weeks
M 48 46 160 2.4 1.1 1.2 + LFT normalized < 18 weeks
M 61 24 60 3.0 1.8 1.5 + LFT normalized < 12 weeks
M 44 48 60 4.8 2.9 5.1 - LFT normalized < 18 weeks
M 30 50 200 1.5 0.4 0.8 + LFT normalized < 6 weeks
M 46 8 80 4.3 3.3 2.2 - LFT normalized < 12 weeks
M 47 25 60 31.9 7.1 7.6 + PEG-V withdrawn, LFT 
normalized
M 47 16 80 14.5 5.9 5.4 - LFT normalized < 12 weeks
M 61 21 60 4.0 2.2 2.0 - LFT normalized < 6 weeks
M 44 60 60 2.9 1.3 2.9 + LFT normalized < 10 weeks
M 54 16 40 4.3 2.4 1.8 - LFT normalized < 8 weeks
F 27 14 60 5.3 3.8 1.7 - LFT normalized < 12 weeks
F 68 8 40 5.5 3.6 2.2 + LFT normalized < 18 weeks
F 66 12 40 2.0 1.2 2.0 + LFT normalized < 18 weeks
F 57 24 60 5.1 2.6 3.0 - LFT normalized < 12 weeks
F 72 40 40 2.1 1.6 0.4 - LFT normalized < 12 weeks
F 45 92 40 2.3 1.2 1.0 - LFT normalized < 3 weeks
F 45 16 40 14.6 8.5 1.4 - LFT normalized < 26 weeks
F 74 68 40 1.8 1.4 2.5 - LFT normalized < 8 weeks
F 47 33 80 1.7 1.3 0.7 + LFT normalized <8 week
F, Female; M, male; LFT, liver function tests; xULN, times upper limit of normal; DM, diabetes mellitus; 
MRCP=Magnetic resonance cholangiopancreatography.
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of treatment. By changing the site of injection more frequently, the lipohypertrophy 
disappeared after 8 months. The PEG-V dose injected by these patients ranged from 
60 mg once weekly to 60 mg twice weekly. None of these patients injected insulin or 
discontinued treatment.
In 12 out of the 86 patients, no tumor size decrease could be assessed due to empty 
sella prior to the start of combined treatment. In 14 (19%) patients out of the remaining 
74 (86-12) patients with an assessable tumor size, the size of the tumor decrease by 
more than 20%, which is considered to be clinically significant. Two patients with tumor 
shrinkage underwent TSS in the past and one also received radiotherapy. The other 12 
patients were on primary medical therapy. In none of the 86 patients was a tumor size 
increase observed.
dISCuSSIoN
We report that long-term combined treatment of long-acting SRIF analog and (twice) 
weekly PEG-V appears to be safe up to more than 57 months. TLEE do occur during 
combined therapy, but they appear to be completely reversible without decreasing 
the dose of PEG-V. When PEG-V is withdrawn and reintroduced after a complete wash-
out of more than 2 months, TLEE reoccur in all our patients. The frequency of TLEE in 
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figure 2: Elevated liver enzymes during combination therapy in 2 patients. Both patients were treated 
with combination treatment for 2 consecutive periods divided by a wash-out period of more than 4 
months. PEG-V = pegvisomant, ALT = alanine aminotransferase, AST = aspartate aminotransaminase, AF 
= alkaline phosphatase, GGT = γ –glutamyltranspeptidase, LD = lactate dehydrogenase and xULN = times 
upper limit of normal.
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our series, with twice weekly PEG-V, is 27% (23/86) versus a report on daily PEG-V 9% 
(21/229) [6]. The frequency is lower when only TLEE of 3x ULN are taken into account (in 
our series in 15.0% (13/86) of the subjects versus 5.2% (12/229) in daily PEG-V [6]. The 
elevated transaminases of 3x ULN all occur within the first year of combined treatment. 
Therefore, assessment of the liver enzymes, as indicated by the package insert of PEG-V, 
is mandatory. Our advice is, close monitoring of the liver enzymes especially in the first 
year, because within this time period the TLEE seem to occur.
Previously, we reported that diabetic acromegalics have a 5.1 (odds ratio) higher risk 
to developing TLEE [2]. In the present study, we observed that diabetic acromegalics 
have a 2.3 times higher risk for developing TLEE. Significance was just lost when TLEE 
of 3 xULN were used for the analysis, probably due to the small number of subjects. 
Apparently, diabetic acromegalic patients should be monitored even more closely, but 
in our series TLEE in diabetic acromegalic subjects appear to be also transient and com-
pletely reversible without discontinuation or dose adjustment of PEG-V. The moment 
of occurrence in diabetic subjects tends to be earlier; however, this was not significant. 
The mechanism behind these PEG-V-induced elevated transaminases is still unknown; 
however, since diabetic acromegalics are more prone to develop the TLEE, it might be 
hypothesized that insulin resistance and lipid accumulation in the liver may predispose 
for these transient elevated transaminases. During the TLEE, no deterioration of the 
glycemic control occurred. It seems to be the other way around. The glycemic control 
is improving, and when there is no further improvement of the glycemic control the 
TLEE rarely occur. Most of these diabetics were on oral drug therapy and no correlation 
between any medication and the occurrence of TLEE could be found.
In this present series, there is no relationship between cumulative dose of PEG-V and 
the TLEE. Patients treated longer than 2 years had no TLEE even though many of them 
have had much higher cumulative dose than patients with TLEE. Patients with higher 
weekly dose of PEG-V did not have higher change for developing TLEE than patients 
with a lower dose.
In our previous QoL study, five subjects developed TLEE [8]. Four of these patients 
participated in our present dose-finding series. All developed TLEE again after the 
re-exposure to PEG-V and TLEE disappeared during continuation. In our hands, the 
combined therapy appears to be safe with regard to TLEE. TLEE are reversible in all our 
patients and seem not to re-occur during continuous PEG-V treatment. Therefore, we 
do not support the drug-warning by the Canadian health authorities that states that 
combination therapy might not be safe due to elevated transaminases.
Our recommendation for the work-up of a patient with TLEE is to closely monitor 
patients in which TLEE of more than 3 times ULN is observed. We advise to exclude 
cholelithiasis in all of these patients. However, in patients with more than 10 times ULN, 
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we advise to perform not only an ultrasound of the liver and bile ducts but also a liver 
biopsy and discontinue PEG-V treatment in the case of drug-induced hepatitis.
Another side effect that was observed was a painless lipohypertrophy in three pa-
tients. In all patients, it resolved within 8 months after changing the injection sites more 
frequently. None of these patients were dissatisfied with their treatment and insisted 
continuation with PEG-V. This is in contrast with another report, in which PEG-V was 
discontinued [11].
An important observation is that in 19% of our patients, we observed a clinically 
significant tumor shrinkage of >20%. The patients with the highest percentage of tumor 
shrinkage are the ones that receive primary medical treatment. This is most likely the 
effect of the continuous treatment with long-acting SRIF analogs. Primary medical-
treated acromegaly patients might show more tumor shrinkage than patients treated 
with adjuvant SRIF analogs [7]. Therefore, we can conclude that long-acting SRIF analogs 
are still able to induce tumor shrinkage, even in the presence of PEG-V. The most im-
portant aspect of our present analyses was safety; however, efficacy is also available. 
In the uncontrolled group of 63 acromegaly patients, 60 (95%) had an IGF1 within the 
age-adjusted normal limits. All three patients with elevated IGF1 started recently with 
combination therapy (range 1.2–4.0) months.
An argument for combined therapy might be the improved QoL that we observed 
when PEG-V was added to long-acting SRIF analog treatment [8]. In addition, the im-
proved insulin sensitivity compared with SRIF analogs alone [12,2], the advantage of 
tumor size control over PEG-V monotherapy [2,6,13], and lower necessary dose of PEG-V, 
which can lead to a cost reduction in at least some patients [1], favor the combined use 
of SRIF analogs and PEG-V. Therefore, we believe that combination therapy deserves a 
prominent place in the medical treatment of acromegaly.
In conclusion, although further research is necessary, our series indicate that com-
bination therapy with long-acting SRIF analogs and twice weekly PEG-V is safe. Mild 
and transient elevated liver enzyme levels were observed in 15% of the patients. Dur-
ing continuation of PEG-V therapy, these liver enzyme abnormalities do not re-occur. 
However, re-exposure to PEG-V treatment after a wash-out period for whatever reason 
will again induce another episode with elevated liver enzymes in those subjects who are 
sensitive for this side effect. Finally, diabetic patients seem to be more prone to develop 
these episodes of transient elevated liver enzyme tests.
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AbSTrACT
Background: The efficacy of combined treatment in active acromegaly with both long-
acting somatostatin analogs (SRIF) and pegvisomant (PEG-V).
Objective: To describe the PEG-V dose reductions after the conversion from daily PEG-V 
to combination treatment. To clarify the individual beneficial and adverse effects, in two 
acromegaly patients, who only normalized their insulin like growth factor (IGF1) levels 
with high-dose pegvisomant therapy.
Design: We present two cases of a 31 and 44 yrs old male with gigantism and acromegaly 
that were controlled subsequently by surgery, radiotherapy, SRIF analogs and daily PEG-
V treatment. They were converted to combined treatment of monthly SRIF analog and 
(twice) weekly PEG-V. High dose SRIF analog treatment was added while the PEG-V dose 
was decreased during carful monitoring of the IGF1.
Results: After switching from PEG-V monotherapy to SRIF analogs plus pegvisomant 
combination therapy IGF1 remained normal. However the necessary PEG-V dose, to 
normalize IGF1 differed significantly between these two patients. One patient needed 
twice weekly 100 mg, the second needed 60 mg once weekly on top of their monthly 
lanreotide Autogel injections of 120 mg. The weekly dose reduction was 80 and 150 mg. 
After the introducing of lanreotide, fasting glucose and glycosylated haemoglobin 
concentrations increased. Diabetic medication had to be introduced or increased. No 
changes in liver tests or in pituitary adenoma size were observed.
Conclusion: In these two patients, PEG-V in combination with long-acting SRIF analogs 
was as effective as PEG-V monotherapy in normalizing IGF1 levels, although significant 
dose-reductions in PEG-V could be achieved. However, there seems to be a wide varia-
tion in the reduction of PEG-V dose, which can be obtained after conversion to combined 
treatment.
Sebastian BW.indd   48 18-Apr-11   15:48:50 PM
Conversion of daily Pegvisomant to weekly Pegvisomant combined with long-acting Somatostatin Analogs 49
INTroduCTIoN
Pegvisomant, a growth hormone (GH) receptor antagonist is a highly effective medical 
therapy for acromegaly. Studies have reported on high efficacy of pegvisomant (PEG-V), 
alone or in combination with somatostatin analogs (SRIF) of >90% to control insulin like 
growth factor (IGF1) [1-4]. The necessary PEG-V dose to control IGF1 seems to be lower 
during combination therapy than with PEG-V alone [5,2]. The combination treatment is 
probably therefore more effective at equal weekly dose than PEG-V alone [5,3,2]. There 
is a necessity to control IGF1 and GH has been well established since this will predict 
mortality [6-7]. So combined treatment seems to be an attractive option.
We present two cases of acromegaly patients who were controlled during daily, 
mono-therapy of PEG-V and were converted to combination treatment.
SubJeCTS ANd MeTHodS
Patients
Case A; A 31-yr-old man was diagnosed with diabetes and gigantism since 1995, with 
a random GH of 220 mU/l and an IGF1 4.5 times the upper limit of normal (x ULN). A 
macro adenoma of 3 cm with suprasellar extension, impingement of the chiasm and 
invasion in the left cavernous sinus which was assessed by the Magnetic Resonance 
Imaging (MRI). In 1996, the initial treatment was transsphenoidal surgery. Pathologist 
reported a pituitary adenoma which a positive immunohistochemical staining for GH. 
Postoperative the GH levels and IGF1 levels remained uncontrolled (table 1). In 1997, 
4 times daily subcutaneous injection of Octreotide 300 μg was started and later con-
verted to Octreotide LAR 30 mg monthly. In 1997, additional radiotherapy of 45 Gy in 
25 fractions was given. In 1998, despite all these efforts IGF1 and GH remained elevated 
while other anterior pituitary hormones became deficient, which needed replacement 
therapy. Therefore, this patient was switched to pegvisomant therapy. Octreotide LAR 
was stopped in 1998 and daily PEG-V was increased up to 40 mg daily until IGF1 was 
within the age adjusted normal limits [4]. In October 2006 Lanreotide autosolution 
(LAN) was added and PEG-V was decreased in dose and frequency according to protocol. 
On pituitary MRI prior to the introduction of the LAN a remnant (8 mm) of the adenoma 
was present in and around left cavernous sinus.
Case B; A 44-yr-old man was diagnosed with acromegaly and osteoporosis since 1994. 
At the time of diagnose random GH serum levels were around 120 mU/l while IGF1 
serum levels were around 3.5 x ULN. On MRI, he had a pituitary tumor of 2-cm with 
suprasellar extension, but without impingement of the chiasm and possible invasion 
of the right cavernous sinus. In 1994 he underwent transsphenoidal surgery. A tumor 
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specimen revealed positive immunohistochemical staining for GH. After surgery, he 
was treated with radiotherapy (42 Gray in 32 fractions). After surgery and RT GH serum 
levels dropped to around 17 µg/l. Three months post surgery IGF1 serum levels were 
decreased to 3.0 x ULN. In 1995, Octreotide was started (100 µg t.i.d.) and converted to 
monthly Octreotide LAR 40 mg in 1998. Although he developed panhypopituitarism 
and GH levels normalized, IGF1 levels remained elevated, around 1.9 x ULN (table 1). In 
2003, Octreotide LAR therapy was switched into PEG-V monotherapy. Daily PEG-V dos-
ages of 30 mg PEG-V were necessary to decrease IGF1 levels to within the age adjusted 
normal limits. In Marche 2007, LAN was added and PEG-V was decreased in dose and 
Table 1.
Patient A
date
1998 2000 2002 2003 jan-07 apr-07 jul-07 oct-07
acromegaly 
medication
Octreotide 
LAR 30
PEG-V 40 
OD
PEG-V 40 
OD
PEG-V 40 
OD
LAN 120
PEG-V 70 
mg TW
LAN 120
PEG-V 80 
mg TW
LAN 120
PEG-V 100 
mg TW
LAN 120
PEG-V 100 
MG TW
GH µg/l 42 N/A N/A N/A N/A N/A N/A N/A
IGF1
ULN 
(nmol/l)
1.9 (73,9) 0.98 (39.3) 0.93 (37.3) 0.93 (37.0) 1.3 (55.7) 1.0(40.9) 0.8(31.4) 0.5 (20.8)
HbA1c 6.9 6.4 6.1 6.2 8.4 8.7 9.0 7.7
Fasting 
glucose
7.3 4.9 5.9 6.5 8.0 9.4 5.7 3.8
 DM 
medication
INN TD 5 INN TD 5 INN TD 5 INN TD 5 INN TD 5 INN TrD 5 INN TrD 5
INN TD 5 
Glargin 48 
IE OD
Patient B
date
2003 2004 2005 2006 jun-07 sep-07 dec-07 mar-07
acromegaly 
medication
Octreotide 
LAR 40
PEG-V 30 
OD
PEG-V 30 
OD
PEG-V 30 
OD
LAN 120
PEG-V 50 
mg TW
LAN 120
PEG-V 80 
mg OW
LAN 120
PEG-V 60 
mg OW
LAN 120
PEG-V 60 
mg OW
GH µg/l 2.3 N/A N/A N/A N/A N/A N/A N/A
IGF1
ULN 
(nmol/l)
1.93 (67.5) 0.82 (28.6) 0.96 (33.6) 0.96 (32.9) 0.3 (12.1) 0.5 (16.6) 0.9 (31.7) 0.8 (29.8)
HbA1c N/A 6.6 6.3 6.4 6.9 7.8 8.9 7.4
Fasting 
glucose
5.7 4.0 4.6 5.0 6.9 10.7 8.9 7.8
 DM 
medication
none none none none none MT 500 TD
MT 850 
TrD
MT 850 
TrD
LAN = Lanreotide Autogel (mg), PEG-V = Pegvisomant (mg), OD = Once Daily, OW = Once Weekly, TW = 
Twice Weekly, TD Twice Daily, TrD Trice Daily, INN = glibenclamide (mg), MT = metformin (mg) and N/A
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frequency. On pituitary MRI prior to the introduction of the LAN, a small (5 mm) remnant 
of the adenoma was present close to the right cavernous sinus.
Methods
After monthly LAN 120 mg was started the intervals between visits were 8 weeks to 
assess efficacy and safety. The initial dose of PEG-V was decreased with 50% and later 
a further stepwise decrease until IGF1 levels escaped (see results section). If IGF1 was 
above the upper limit of normal the dose was increased again until IGF1 levels were 
within the age adjusted normal range. If IGF1 fell below 0.5 ULN PEG-V dose was de-
creased. After normalization of IGF1 during the combination treatment phase, subjects 
visited our outpatient clinic every 12-16 weeks. If a pegvisomant injection dose reached 
100 mg or more, the administration of pegvisomant was divided into 2 (equal) dosages 
that were injected twice weekly.
From 2004 to 2009, IGF1 and GH concentrations were measured by an immunometric 
assays (Diagnostic Products Corporation, Los Angeles USA) and before by an immuno-
radiometric assays (Diagnostic Systems Laboratories, Texas USA). The IGF1 age adjusted 
reference ranges were used [8]. But during PEG-V treatment the GH serum levels were 
not assessed.
Safety assessment included: Fasting glucose, glycosylated haemoglobin, EKG, serum 
concentrations of alkaline phosphatase , γ –glutamyltranspeptidase (γ-GT), alanine ami-
notransferase (ALT), aspartate aminotransaminase (AST), lactate dehydrogenase, total 
bilirubin and change in pituitary tumor volume. Tumor volume was assessed at baseline 
by MRI which was repeated every 12 months. Change in pituitary adenoma size was 
assessed by the same neuro-radiologist.
reSulTS
LAN 120 mg was given every 4 weeks. After the second administration of LAN 120 mg 
PEG-V dose was decreased by 50% of the normal total weekly dose of the subjects. 
PEG-V was increase until IGF1 normalized after 3 and/or 6 months (table1). Patient A 
was on 40 mg PEG-V, daily. Patient’s B original dose was 30 mg a day of PEG-V. The dose 
reduction of PEG-V in patient A started with a dose decrease to twice weekly 70 mg of 
PEG-V. Patient B decreased the PEG-V to twice weekly 50 mg. After 3 months patient A 
increased the dose to twice weekly 80 mg and patient B decreased the dose to 80 mg 
once weekly. After 6 months the final dose for patient A was twice weekly 100 mg and 
for patient B once weekly 60 mg of PEG-V. The weekly PEG-V dose reduction for patient A 
was 80 mg and patient B, 150 mg weekly, both with a normalized IGF1 (figure 1).
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SAfeTy
Fasting glucose and glycosylated haemoglobin levels increased after introduction of 
LAN (Table 1). In patient 1, additional diabetic medication was necessary. Glargine up 
to 48 IE was added on top of glibenclamide (5 mg b.i.d). Patient 2 had to start diabetic 
medication (metformin 850 mg t.i.d.; table 1). In these patients no transient elevated 
liver enzyme tests or tumor size increase was observed.
dISCuSSIoN
We report two adequate controlled acromegaly patients during PEG-V monotherapy. 
Both could also be controlled after the conversion to combined treatment of PEG-V with 
long-acting SRIF analogs. During combined treatment, a dose reduction of PEG-V could 
be obtained between 80-150 mg weekly to keep IGF1 levels within the age-adjusted 
reference range.
During long-term combined therapy the weekly mean dose of PEG-V was 77 mg 
[2,9] while with PEG-V monotherapy a weekly mean dose of 130 mg was necessary to 
reach an equal efficacy rate of more than 90% [4]. Data from the long-term surveillance 
AcroStudytm indicate that the mean patient on PEG-V therapy (of which around 1 out of 
4 also use SRIF analogs) needs more than 21 mg of PEG-V daily with an efficacy rate of 
around 60% [10]. In our 2 patients that needed high-dose PEG-V during monotherapy, 
we observed dose reductions of 80 & 150 mg per week, which reflect reductions in an-
0.4
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figure 1: Course of IGF1 during different treatment modalities.
1: Octreotide LAR, 2a Pegvisomant 40 mg daily, 2b Pegvisomant 30 mg daily, 3a & 3b Somatuline autogel 
and Pegvisomant
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nual costs of around 35.000 - 65.000 € respectively. When we take into consideration 
that high-dose SRIF analogs treatment costs between 19.000 – 25.000 €, depending on 
the country, our data indicate that in patients who need high-dose PEG-V during mono-
therapy, a significant reduction in costs can be achieved without loosing efficacy in 
normalizing IGF1 levels. The ratio behind the dose reduction in PEG-V during combined 
therapy of LAN and PEG-V is an increase of about 20% in PEG-V serum levels [11,4] and 
the decrease in GH serum levels due to SRIF analog treatment. Also, a direct and indirect 
inhibition of IGF1 generation of the liver by SRIF analogs [11,4,12,2,13-14] has been 
reported. Thus, during combined treatment PEG-V, which is a competitive antagonist of 
the GH receptor (GHR), has less GH to compete with, which reduces the necessary dose 
of PEG-V. Moreover, experiments in rodents, observed a decrease in the number of GHR 
on the liver due to a decrease of portal insulin concentration, which is a direct effect of 
SRIF analogs [12,15-16]. Therefore a further reduction in PEG-V dose can be possible.
The difference in dose reduction we observed between both patients might be ex-
plained by the expression level of subtype of the somatostatin receptor (SSTR) on the 
pituitary adenoma. Patient 1 might have a lower expression of sst2 than patient B, as 
the efficacy of SRIF analogs in suppressing pathological GH secretion depends on the 
expression level of the sst subtypes on the pituitary adenoma [17]. The expression level 
of sst2 on human pancreatic beta cells is high, but there remains controversy on the 
expression of sst3 and sst5 [18]. In vivo, octreotide, mainly an sst2 agonist, decreases 
insulin concentration in contrast to Pasireotide (SOM 230) [17]. Pasireotide, with high 
affinity to the sst1 and sst5 as well , has as Octreotide hyperglycemic effect. There for it 
unclear what the effect of SOM 230 is on the GHR expression on the liver. The alternative 
treatment with SOM 230 in patient 1 might lead to a dose reduction since GH levels 
will be lower but because of the possible higher expression of GHR a higher dose could 
be needed. Thus it is unclear what the net effect will be beneficial for the PEG-V dose 
reduction. Finally most studies which have been conducted with SOM230 where with 
diabetic patient that had an optimal control. Therefore it is questionable if this patient 
would really benefit from SOM 230.
SRIF analogs inhibits both exocrine and endocrine hormone secretion and to a 
lesser extent neuroendocrine tumor cell proliferation [19]. Activation of sst receptors 
decreases intra-cellular c-AMP generation through the inhibition of adenylyl cyclase. 
There seems to be a role of the GHRH –cAMP signaling pathway in somatotroph tumor-
genesis. Ectopic GHRH production leads to somatotroph hyperplasia, however rarely to 
adenoma formation [20]. GHRH induces c-AMP via a G-protein coupled receptor, the 
GHRH receptor, which induces GH production. Guanine nucleotide-binding protein 
(GNAS) mutation can lead to constitutively elevated c-AMP, protein kinase A activity, 
GH synthesis and secretion [21]. About 40% of sporadic somatotroph adenomas harbor 
this mutation. Although the percentage of patients using PEG-V that develop a clinical 
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significant increase in tumor size is reassuring low [22-23], the inhibitory effects of SRIF 
analogs on these mechanisms that are related to tumor growth also would suggest a 
more prominent role for the combination of both SRIF analogs and PEG-V, especially in 
patients with aggressive tumors and active disease that need high dose PEG-V during 
PEG-V monotherapy.
The disadvantage of SRIF analogs treatment compared to PEG-V treatment with re-
spect to carbohydrate metabolism is clearly demonstrated here. In healthy volunteers, 
administration of PEG-V did not influence the fasting insulin and glucose or response to 
oral glucose loading, in contrast with octreotide [24]. Short term combined treatment 
resulted in a lower fasting glucose than with SRIF analogs alone, without a change in 
insulin levels [11]. During long-term studies a decrease in glycosylated haemoglobin 
could be observed despite the reduction of insulin or oral diabetic medication [3,2]. It 
seems that in the hierarchy of the beneficial effects on carbohydrate metabolism, PEG-V 
as monotherapy is superior to combined treatment. However, the combination is better 
than SRIF analogs monotherapy.
In the past, both patients were treated with conventional radiotherapy. This was 
the pre-PEG-V era. To date, radiotherapy has become redundant from efficacy point of 
view. After a mean duration of 10 years remission rates of 50-60% are reported, but also 
50-80% of subjects develop hypopituitarism as well [25]. Radiotherapy has some more 
disadvantages. A decreased quality of life has been reported which seems to be progres-
sive over time [26] and radiotherapy might also increase mortality (SMR 2.68) mainly 
due to cerebrovascular mortality [27]. Our patients already showed some long-term side 
effects of radiotherapy as both have hypopituitarism. Cerebrovascular accidents have 
not occurred to date.
These two cases are different from our previous reports, because these two patients 
were previously treated controlled with PEG-V daily monotherapy. Our previous studies 
included patients on SRIF analogs that still had an elevated IGF1 and therefore we did 
not have a direct comparison for dose reduction of PEG-V.
In this case-study we start immediately with high-dose SRIF analogs treatment and 
we reduce weekly dose of pegvisomant by 50%. After 3 and 6 months, the PEG-V can be 
adjusted according to the serum IGF1 levels, If elevated, a higher weekly dose is neces-
sary, while in case of normal IGF1 levels, one could further reduce the PEG-V dosages to 
find the lowest effective dose.
In conclusion, these two case-reports show that a dose reduction in PEG-V is possible 
after the addition of a monthly high dose SRIF analogs. This might significantly reduce 
the annual costs. However, deterioration in the carbohydrate metabolism should be 
taken into account.
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AbSTrACT
Objective: The objective of the study was to assess whether weekly administration of 
40 mg pegvisomant (PEG-V) improves quality of life (QoL) and metabolic parameters in 
acromegalic patients with normal age-adjusted IGF1 concentrations during long-acting 
somatostatin analog (SRIF) treatment.
Design: This was a prospective, investigator-initiated, double blind, placebo-controlled, 
crossover study. Twenty acromegalic subjects received either PEG-V or placebo for 
two consecutive treatment periods of 16 wks, separated by a washout period of 4 wks. 
Efficacy was assessed as change between baseline and end of each treatment period. 
QoL was assessed by the Acromegaly Quality of Life Questionnaire (AcroQoL) and the 
Patient-Assessed Acromegaly Symptom Questionnaire (PASQ).
Results: The AcroQoL (P = 0.008) and AcroQoL physical (P = 0.002) improved significantly 
after PEG-V was added. The addition of PEG-V also significantly improved the PASQ (P = 
0.038) and the single PASQ questions, perspiration (P = 0.024), soft tissue swelling (P = 
0.036), and overall health status (P = 0.035). No significant change in Z-score of IGF1 (P 
= 0.34) was observed during addition of PEG-V. Transient liver enzyme elevations were 
observed in five subjects (25%).
Conclusion: Improvement in quality of life was observed without significant change in 
IGF1 after the addition of 40 mg pegvisomant weekly to monthly SRIF analogs therapy 
in acromegalic patients who had normalized IGF1 on SRIF analogs monotherapy. These 
data question the current recommendations in how to assess disease activity in acro-
megaly. Moreover, the findings question the validity of the current approach of medical 
treatment in which pegvisomant is used only when SRIF analogs therapy has failed to 
normalize IGF1.
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INTroduCTIoN
Recent improvement in the medical treatment of acromegaly has resulted in better 
biochemical disease control in virtually every acromegaly patient [1-4]. By normal-
izing both IGF1 and GH, the elevated long-term mortality will decrease [5-8]. However, 
normalization does not completely relieve patients from their symptoms [9]. From the 
patient’s perspective an important parameter of disease control is the quality of life 
(QoL). Indeed, these residual symptoms result in an impaired QoL [10-13]. To quantify 
the symptoms and QoL in patients with acromegaly, the Patient-Assessed Acromegaly 
Symptom Questionnaire (PASQ) [3-4] and the Acromegaly Quality of Life Questionnaire 
(AcroQoL) have been developed [14].
We recently reported that the combination of somatostatin analog (SRIF) and (twice) 
weekly pegvisomant (PEG-V) is an effective treatment for patients in whom the IGF1 
remains elevated during SRIF analog monotherapy [1-2]. The rationale for this combined 
treatment is based on the concept that SRIF analogs will decrease GH secretion in ac-
romegalic subjects. When there is less endogenous GH to compete for the GH receptor 
(GHR), less of the GHR antagonist PEG-V is needed. Moreover, in vitro data suggest that 
the inhibition of insulin secretion by SRIF analogs in the portal vein results in a reduction 
of GHR on the cell surface of hepatocytes [15]. So when there are fewer hepatic GHRs 
and less endogenous GH, less PEG-V is necessary. Finally, SRIF analogs can also directly 
inhibit IGF1 production by hepatocytes [16]. Therefore, SRIF analogs makes the liver less 
GH sensitive, as the rest of the body might still be slightly acromegalic. If these extra-
hepatic GH actions could be antagonized by the addition of pegvisomant, one might 
observe an improvement of QoL.
We therefore performed a randomized, double-blind, placebo-controlled, crossover 
study in which we assessed QoL, using AcroQoL and PASQ, in acromegalic patients in 
biochemical remission on long-term SRIF analog monotherapy before and after the ad-
dition of a weekly dose of 40 mg PEG-V for a period of 16 wks.
PATIeNTS ANd MeTHodS
Patients
Twenty acromegalic patients, median age 56 (range 39–74) yr, with an IGF1 within the 
age adjusted normal range during long-term long-acting SRIF analog therapy, were 
enrolled in this study [17]. All subjects were on a stable long-acting monthly SRIF analog 
treatment for at least 36 months. The single GH levels assessed before the initiation of 
PEG-V therapy were less than 2.5 µg/liter in all but one subject. Patients’ characteristics 
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are presented in Table 1. All patients gave their written informed consent, and the study 
was approved by the local ethics committee.
design
The study was a prospective, investigator-initiated, double-blind, placebo-controlled, 
single-center, crossover study. After enrollment [visit (V)], patients were randomized to 
receive a single weekly sc injection of 40 mg PEG-V or placebo. QoL assessment and 
biochemical evaluation were performed at baseline and after 8 (V2) and 16 wks (V3) 
of combined treatment. After a 4-wks washout period (V4), patients were switched to 
either placebo or PEG-V for another 16 wks (V5 at 28 wks and V6 at 36 wks).
At all visits efficacy and safety data were assessed including two QoL-questionnaires, 
IGF1, glycosylated hemoglobin, fasting glucose, insulin, lipids and homeostasis model 
assessment insulin resistance. Additional safety including serum alkaline phosphatase, 
-glutamyltranspeptidase, alanine aminotransferase, aspartate aminotransaminase, 
lactate dehydrogenase, and total bilirubin were measured, and each subject had an 
electrocardiogram. IGF1, insulin, and GH concentrations were measured by immuno-
Table 1. Baseline characteristics
Number# (%)#
Patients 20 (100)
Sex (female) 9 (45)
Age (years)
Mean (SD, range) 55 (10.0, 39-74)
diabetes Mellitus 3 (15)
growth hormone (μg/l) at baseline
Mean (SD) 1.12 (0.7)
Median (range) 1.0 (0.2-3.1)
Previous treatment
TSS 15 (75)
Both TSS and radiotherapy 6 (30)
Primary medical therapy 5 (25)
Pituitary insufficiency 
Panhypopituitarism 5 (25)
1-2 axis 11 (55)
No hypopituitarism 4 (20)
long-acting somatostatin analogs
Lanreotide 8 (40)
Octreotide 12 (60)
#Unless otherwise specified TSS= Transsphenoidal Surgery RT= radiotherapy
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metric assays (Immulite 2000; Diagnostic Products Corp., Los Angeles, CA). For IGF1 the 
intra- and interassay coefficients of variation are 4.9–6.3 and 3.5–7.5%, respectively [18]. 
IGF1 age-adjusted reference ranges were used to calculate the Z-score of the IGF1 [17].
At baseline and last visit of the study, a magnetic resonance imaging of the pituitary 
was performed to detect any change in pituitary volume during the study. An inde-
pendent physician, who did not participate in the study and was unblinded for the 
medication, evaluated the laboratory findings after each visit to ensure safety and the 
double-blind set-up of the study. If elevated liver enzyme tests were higher than 4 
times the upper limit or normal (ULN) during the treatment periods, the patients were 
withdrawn from the study.
Questionnaires
AcroQol
AcroQoL comprises 22 questions. Each question has five possible answers scored 1–5, 
with a total maximum score of 110 and quoted as a percentage. The score of 110 reflects 
the best possible QoL. The 22 questions are divided into two main categories: physical 
and psychological function. The psychological dimension is subdivided into appear-
ance and personal relationships [19,14]. The AcroQoL has a good internal consistency 
(Cronbach’s > 0.7) [20].
PASQ
The PASQ is a disease-specific questionnaire, which consists of six questions scoring 0–8 
and the seventh question addressing the overall health status, based on the other six 
questions, scoring 0–10 [3-4]. The first six questions evaluate symptoms as headache, 
excessive sweating, joint pain, fatigue, soft tissue swelling, and numbness or tingling 
of the extremities. The maximum score of these six questions is 48 and indicates severe 
signs and symptoms, with lower scores reflecting improved QoL.
Statistics
For the analysis of QoL questionnaires, the change between baseline and end of each 
treatment period with pegvisomant (PEG-V) and with placebo (placebo) was calculated. 
By assessing the change in QoL-questionnaire scores, between baseline and follow-up, 
possible confounder were taken into account when the paired of these patients were 
analyzed. The IGF1 results are expressed as Z-score. Therefore, they are reported in SD 
units. Sample size calculation was made, based on expected PASQ scores, anticipating 
that SD of each group (assuming they are equal) is 2.5 on the scale of 0–8. When choos-
ing = 0.05, two-tailed, and power = 80%, a number of 20 patients per group will enable 
detection of differences of 1.82.
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The paired data were analyzed with the Wilcoxon’s signed rank test. The correlation 
between the nonparametric data was assessed by the Spearman’s rank correlation. 
Statistical analyses were performed by GraphPad Prism (version 5.00 for Windows; 
GraphPad Software, San Diego, CA). Statistical significance was accepted at P < 0.05 
(two tailed). Data are nonparametric and therefore expressed as median ± SD unless 
otherwise specified.
reSulTS
All 20 patients completed the study. At baseline, all IGF1 levels were within the age-
adjusted normal range and GH was 2.5 µg/liter or less in all except for one subject (GH 
of 3.1 µg/liter). The QoL scores, parameters of metabolic control, and body weight are 
presented in Table 2.
Table 2. Quantitative changes in QoL in two groups induced by the addition of 40 mg PEG-V once weekly 
in two different groups of acromegalic patients (PEG-V-placebo, Table 2A, and placebo-PEG-V, Table 2B) 
with normal IGF1 during long-term treatment with SRIF analogs.
2A Baseline PEG-V After 
wash-out
Placebo
Peg-v Placebo group
Z-score of IGF1 1.50
(1.04-1.73)
1.46
(-0.09-1.58)
1.45
(0.89-1.84)
1.64
(1.03-1.99)
Body weight (Kg) 83.1
(69.7-107.7)
82.1
(70.3-106.6)
81.6
(70.4-107.3)
83.0
(69.4-106.2)
AcroQol global (%) 64.2
(44.3-79.5)
69.9
(39.8-87.5)
66.5
(31.8-88.6)
68.2
(30.7-86.0)
AcroQol physical (%) 51.7
(37.5-92.0)
62.5
(40.6-93.8)
53.1
(31.3-96.9)
59.4
(28.1-87.5)
AcroQol psychological 
(%)
65.2
(48.3-87.5)
70.5
(39.3-85.8)
70.5
(32.1-89.3)
72.3
(32.2-85.7)
AcroQol pers, relation 
(%)
82.1
(53.6-96.4)
82.1
(46.4-100.0)
80.4
(42.9-100.0)
82.1
(35.7-100.0)
AcroQol
appearance (%)
50.0
(21.4-85.7)
62.5
(28.6-82.1)
64.3
(21.4-82.1)
62.5
(28.6-82.1)
PASQ 14.0
(2.0-21.0)
10.0
(0.0-17.0)
7.5
(0.0-20.0)
10.0
(3.0-22.0)
PASQ headache 1.0
(0.0-3.0)
1.0
(0.0-4.0)
0.0
(0.0-3.0)
1.5
(0.0-4.0)
PASQ excessive 
sweating
1.0
(0.0-5.0)
0.0
(0.0-3.0)
0.0
(0.0-1.0)
1.0
(0.0-4.0)
PASQ joint pain 4.0
(0.0-6.0)
3.0
(0.0-8.0)
2.5
(0.0-8.0)
3.0
(0.0-7.0)
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Table 2. (continued)
Baseline PEG-V After
wash-out
Placebo
PASQ fatigue 3.5
(1.0-6.0)
4.0
(0.0-6.0)
2.0
(0.0-6.0)
2.5
(1.0-6.0)
PASQ soft tissue 
swelling
2.0
(1.0-3.0)
0.5
(0.0-2.0)
0.5
(0.0-3.0)
0.5
(0.0-3.0)
PASQ numbness
or tingling
1.5
(0.0-5.0)
1.0
(0.0-1.0)
1.0
(0.0-1.0)
0.5
(0.0-3.0)
PASQ overall
health status
3.0
(2.0-7.0)
1.5
(0.0-6.0)
1.5
(0.0-6.0)
3.0
(1.0-6.0)
2B baseline
(median (range))
Placebo
(median (range))
After wash-out Peg-v
(median (range))
Placebo Peg-v group
Z-score of IGF1 1.66
(0.82-2.03)
1.52
(0.80-1.92)
1.57
(0.89-1.86)
1.67
(1.26-1.93)
Body weight (Kg) 96.8
(69.7-115.8)
95.5
(70.3-117.3)
95.4
(70.4-115.8)
93.7
(69.4-115.1)
AcroQol
global (%)
52.9
(22.7-93.2)
57.4
(22.7-96.6)
54.0
(23.9-95.5)
59.4
(28.4-96.7)
AcroQol
physical (%)
43.9
(18.8-87.5)
40.7
(18.8-90.6)
43.9
(15.6-90.6)
45.3
(34.4-94.4)
AcroQol
psychological (%)
60.7
(21.5-98.2)
69.6
(21.4-100.0)
64.3
(25.0-98.2)
68.8
(25.0-98.0)
AcroQol
pers, relation (%)
71.4
(25.0-100.0)
66.1
(25.0-100.0)
64.3
(25.0-100.0)
71.1
(25.0-100.0)
AcroQol
appearance (%)
55.4
(17.9-96.4)
64.3
(17.9-100.0)
55.3
(25.0-96.4)
64.3
(25.0-96.6)
PASQ 23.5
(9.0-37.0)
26.5
(3.0-39.0)
25.0
(4.0-40.0)
22.0
(5.0-39.0)
PASQ
headache
5.0
(0.0-6.0)
3.5
(0.0-7.0)
5.0
(0.0-7.0)
3.0
(0.0-7.0)
PASQ excessive 
sweating
4.5
(0.0-6.0)
4.5
(0.0-7.0)
3.5
(0.0-7.0)
4.0
(0.0-7.0)
PASQ
joint pain
4.5
(2.0-7.0)
5.0
(0.0-8.0)
5.0
(2.0-8.0)
4.5
(0.0-8.0)
PASQ
fatigue
4.5
(2.0-8.0)
5.5
(1.0-7.0)
5.0
(0.0-8.0)
5.0
(0.0-7.0)
PASQ soft tissue 
swelling
1.5
(0.0-6.0)
3.0
(0.0-5.0)
2.5
(0.0-7.0)
3.0
(0.0-5.0)
PASQ numbness
or tingling
3.5
(0.0-8.0)
4.0
(0.0-7.0)
3.5
(0.0-7.0)
3.5
(0.0-7.0)
PASQ overall
health status
4.5
(1.0-7.0)
4.5
(1.0-8.0)
4.5
(1.0-8.0)
4.5
(0.0-7.0)
All value are expressed as (median (range)); IGF1 = insulin-like growth factor-I; PEG-V = pegvisomant; 
PASQ = Patient-assessed; AcroQol = Acromegaly Quality of Life Questionnaire
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AcroQol
The AcroQoL improved significantly after the addition of PEG-V (PEG-V 6.4 ± 4.25%, 
placebo –1.1 ± 7.12%, P = 0.008, Fig. 1 and Table 2). PEG-V increased QoL in the AcroQoL 
physical (PEG-V 8.0 ± 7.88%, placebo 0.0 ± 6.25%, P = 0.002, Fig. 1 and Table 2). However, 
the AcroQoL psychological (PEG-V 3.6 ± 6.09%, placebo –0.9 ± 9.36%, P = 0.185), Acro-
QoL appearance (PEG-V 4.0 ± 7.97%, placebo –2.0 ± 12.09%, P = 0.409), and personal 
relations (PEG-V 0.0 ± 6.14%, placebo –4.0 ± 9.66%, P = 0.109) tended to increase with 
the addition of PEG-V but failed to reach significance.
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figure 1: A, Changes in AcroQoL induced by the addition of 40 mg PEG-V once weekly in two different 
groups of acromegalic patients (PEG-V-placebo and placebo-PEG-V) with normal IGF1 during long-term 
treatment with SRIF analogs. *, P = 0.013 for T0 vs. T16; °, P = 0.001 for T20 vs. T36. B, Changes in AcroQol 
physical after the addition of placebo or PEG-V for the two different groups PEG-V-placebo and placebo-
PEG-V. *, P = 0.006 for T0 vs. T16; °, P = 0.019 for T20 vs. T36. The mean and SEM values are given for each phase 
of the study. The baseline AcroQoL score is expressed as 1 and the other intervals (T 16, T 20, and T 36 wks) 
as ratio of baseline QoL.
PASQ
The PASQ changed significantly (P = 0.038) after cotreatment with PEG-V (PEG-V –2.0 ± 
6.60, placebo 1.5 ± 5.02, Fig. 2). In the six questions of the PASQ addressing the different 
symptoms, a significant decrease in signs and symptoms was observed in the questions 
soft tissue swelling (PEG-V –0.5 ± 1.37, placebo 0.0 ± 1.28, P = 0.024), excessive sweating 
(PEG-V 0.0 ± 1.79, placebo 0.5 ± 0.98, P = 0.036), and overall health status (PEG-V –1.0 
± 1.99, placebo 0.5 ± 1.36, P = 0.035, Fig. 2) when PEG-V was added. The joint pain did 
not improve significantly (PEG-V –1.0 ± 1.47, placebo 0.0 ± 1.49, P = 0.083). In the other 
parameters, headache (P = 0.899), fatigue (P = 0.662), or numbness or tingling of the 
extremities (P = 0.175), no significant improvement was observed.
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Metabolic parameters
The combined treatment of PEG-V and SRIF analog did not result in a significant change 
the Z-score of IGF1 (PEG-V –0.064 ± 0.380, placebo 0.102 ± 0. 317, P = 0.341) or in abso-
lute IGF1 concentration (P = 0.444, Fig. 2). The insulin-dependent metabolic parameters 
as homeostasis model assessment insulin resistance (P = 0.808, Fig. 3C), glycosylated 
hemoglobin (P = 0.241), and fasting glucose (P = 0.955) did not change significantly ei-
ther. During PEG-V treatment, total cholesterol (TC) and low-density lipoprotein tended 






	 
 






A
 







	 
















b






	 














C
 






	 
 














d






	 













e
 





	 













f
figure 2: Change in PASQ and metabolic parameters induced by the addition of 40 mg PEG-V once 
weekly in two different groups of acromegalic patients (PEG-V-placebo and placebo-PEG-V) with normal 
IGF1 during long-term treatment with SRIF analogs. A, Total PASQ score. B, PASQ subscore excessive 
sweating. C, PASQ subscore soft tissue swelling. D, PASQ overall health status. E, Change in Z-score of IGF1 
induced by the addition of 40 mg PEG-V once weekly in two different groups of acromegalic patients 
(PEG-V-placebo and placebo-PEG-V) with normal IGF1 during long-term treatment with SRIF analogs. F, 
Change in body weight induced by the addition of 40 mg PEG-V once weekly in two different groups of 
acromegalic patients (PEG-V-placebo and placebo-PEG-V) with normal IGF1 during long-term treatment 
with somatostatin analogs. Box whisker plots are expressed in minimum, median, and maximum.
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to decrease; however, these changes were not significant; TC PEG-V was –0.35 ± 1.04 
(median ± SD) and TC placebo was 0.10 ± 1.12 (P = 0.091). The low-density lipoprotein 
PEG-V was –0.19 ± 0.72 and placebo 0.20 ± 0.75 (P = 0.055). In the other lipids (P > 0.05) 
and the free fatty acids (P = 0.231), no change was observed. We observed no decrease 
in body weight in the whole group of subjects treated with PEG-V and SRIF analog 
(PEG-V –0.95 ± 1.70, placebo –0.40 ± 1.60, P = 0.081, Fig. 2), although some individuals 
showed a remarkable decrease in their body weight during their treatment period with 
both SRIF analog and PEG-V.
Correlations
The correlations between the parameters of QoL and biochemical and phenotypical pa-
rameters are presented in Fig. 3. Neither the change in the score of IGF1 nor the baseline 
GH levels correlated with changes in QoL. Changes in body weight correlated well with 
the observed improvements in QoL by the AcroQoL physical (r = –0.449, P = 0.047, Fig. 
3) and the PASQ joint pain (r = 0.489, P = 0.029), excessive sweating, and soft tissue 
swelling, which are all QoL entities that reflect increased GH actions.
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figure 3: Correlation between the change in AcroQoL and the Z-score of IGF1 (A) and change in body 
weight (B). Correlation between the change in AcroQoL, category physical (AcroQoL physical) and the 
Z-score of IGF1 (C) and change in body weight (D).
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Safety
Transient elevated liver enzyme tests (TLETs) were observed in five patients (25%) but 
did not necessitate discontinuation of PEG-V treatment. In one patient TLETs up to 9 
times the ULN were observed during her last visit of the PEG-V treatment period. Be-
cause it was at the end of the treatment period, she was not withdrawn from the study. 
TLETs up to a maximum of 4 ULN were observed in another four subjects. The duration 
of TLETs was 8.0 wks median with a SD of ± 5.4. Of these five patients with TLETs, two 
patients also suffered from diabetes mellitus (40%). As expected, no change in pituitary 
volume was observed in any of the subjects.
dISCuSSIoN
Our study has two important messages. The first is that a significant improvement in QoL 
can be observed without a significant decrease in IGF1 after the addition of 40 mg PEG-V 
weekly in acromegalic patients with IGF1 concentrations within the age-adjusted range 
during SRIF analog treatment. This observation questions the current strategy in which 
PEG-V is used only as monotherapy or in combination with SRIF analog after IGF1 failed 
to normalize during monotherapy with long-acting SRIF analogs. It is noteworthy that 
the magnitude of the improvement in AcroQoL-score of 6.4% in this study is equal to 
the observations of Paisley et al. [21] [6.8% (–11.4 to 26.1)]. In their study, this change in 
QoL was observed when elevated IGF1 was reduced to the age adjusted normal range.
Although in some individuals IGF1 levels clearly decreased during PEG-V cotreat-
ment, for the whole group, IGF1 did not decrease significantly. This observation might 
be explained by an observation by Segev et al. [22], who reported that a GH receptor 
antagonist in rodents was able to block GH actions, in their case in the kidney at lower 
concentrations than were necessary to decrease serum IGF1 and somatic growth. How-
ever, our study was powered to detect a difference in PASQ score and not designed to 
detect a difference in IGF1. Therefore, it is possible that studies in larger populations will 
observe a significant decrease.
The current consensus on the goals of treatment of acromegaly has focused on nor-
malization of IGF1 and GH and thereby reducing long-term morbidity and mortality [23-
24]. However, the normalization of levels of total serum IGF1 and GH do not necessarily 
reflect optimal QoL in acromegalic patients [10-12,9,13]. The second important message 
of our study is that total serum IGF1 levels, assessed by the commercially available IGF1 
assays, do not correlate well enough with the QoL of the patient to use them for defining 
proper biochemical control.
In our study the improvement of QoL correlated with other GH-dependent param-
eters such as loss of body weight, perspiration, soft tissue swelling, and the AcroQoL 
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physical, strongly suggesting that in these patients, integrated GH action is too high, 
despite normal IGF1 levels. GH action is known to increase extracellular volume [25]. 
GH activates the renin-angiotensin-aldosterone system, which leads to fluid retention 
when GH concentrations are high [26-27]. These observations could explain the changes 
we observed in GH dependent parameters. We observed a significant improvement in 
the physical dimension of the AcroQoL and not in the dimension appearance, which 
is mostly affected in the chronic phase of acromegaly. This might be explained by the 
short duration (16 wks) of coadministration of PEG-V, resulting in an acute change that 
is perceived physically but not as a change in appearance.
The mode of action of SRIF analogs might also explain why the addition of PEG-V 
improves QoL. The effects of SRIF analog therapy on GH actions are not only mediated by 
the reduction of pathological GH secretion by the pituitary adenoma, but SRIF analogs 
also reduces insulin secretion in the portal vein. This mechanism will most likely reduce 
the available GH receptors on the liver [15]. Finally, SRIF analogs are able to directly reduce 
IGF1 production by hepatocytes [16]. These mechanisms are the basis of the concept that 
the combined use of SRIF analogs and pegvisomant should be able to reduce the dosage 
and frequency of pegvisomant administration, and indeed they do [1]. These mechanisms 
also suggest that whereas the liver is made relatively GH resistant, the rest of the body is 
still slightly acromegalic during SRIF analog treatment. One might then expect that the 
treatment of this extrahepatic acromegaly with low-dose weekly PEG-V administration 
would therefore improve the GH-dependent signs and symptoms and QoL, and indeed 
this was observed. The dose of 40 mg of PEG-V per week was pragmatically chosen as 
being about half the starting dose of PEG-V monotherapy, and the optimal dose has not 
been determined by this study. Nor do we know whether a further increase in QoL can be 
achieved by another dose of PEG-V that would decrease serum IGF1 levels.
We believe that our data might be important for treatment of acromegaly when 
medical treatment is concerned. The available consensus statements aim at just normal-
izing IGF1 to within the age-adjusted normal range [23-24]. They more or less ignore 
signs and symptoms of patients the moment IGF1 has become normal. However, from 
a patient’s perspective, just normalization of serum IGF1 levels might not be enough. 
Our data suggest that most patients seem to know exactly what optimal treatment is, 
and they favor a combined approach by which both SRIF analogs and PEG-V play their 
specific roles. This suggests that we should abandon the step-up approach and that we 
should investigate the role of the combined approach in larger series of patients. Apart 
from the statistical outcome of the study, what really impressed us was the fact that 80% 
of subjects knew in retrospect which of the two treatment periods was the one in which 
they had received PEG-V, which is striking in a double-blind study design. They not only 
recognized the presence of PEG-V but also insisted in getting it back the moment the 
study was finished.
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TLETs were observed in five patients (25%) of which two subjects also suffered from 
diabetes. Furthermore, as expected in this short study of 4 months of PEG-V exposure, 
no change in pituitary adenoma size was observed. No change in overall insulin sensitiv-
ity or change in lipids in the whole study population was observed. However, this could 
be due to a type 2 error or to our short treatment period of 16 wks because others have 
observed improvement [28]. One patient had to reduce her oral diabetic medication 
due to frequent hypoglycemic episodes during PEG-V treatment period. Five weeks after 
withdrawal of PEG-V, the dose of diabetic medication had to be increased again.
It is internationally accepted that in most studies, a 2-wks period between test and 
retest is enough to avoid for the memory effect [29-30]. In our study we assessed QoL 
during a 4-month period so we think that memory could not have any impact on the 
scores.
In conclusion, QoL in acromegalic patients who normalized serum IGF1 concentra-
tions during long-term treatment with long-acting SRIF analogs can be significantly 
improved by the addition of a weekly dose of 40 mg pegvisomant. This improvement 
is not accompanied by a significant decrease in serum IGF1 levels, which questions the 
importance of total serum IGF1 as a reliable parameter for QoL from a patient’s perspec-
tive. Our data also question the step-up approach in which patients are treated only 
with pegvisomant when somatostatin analog monotherapy was not able to normalize 
IGF1 levels. These findings warrant further investigation on the efficacy and safety of 
adding pegvisomant to SRIF analog therapy in most acromegalic patients.
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AbSTrACT
Background: Of the currently available treatment regimes for acromegaly, pegvisomant 
(PEG-V) has the highest efficacy. During PEG-V treatment, growth hormone (GH) serum 
levels increase. The exact mechanism behind this is remains unclear. It could be ex-
plained by an ultra-short feedback loop via GH receptors (GHR) in the anterior pituitary 
gland, but than GHR should be present in the adenoma
Objective: To assess the level of GHR mRNA expression in somatotroph adenomas and to 
evaluate whether GHR blockade by PEG-V can lead to an increase in GH levels.
Design: In 32 somatotroph adenomas and 4 samples of human liver tissue, after RNA 
extraction, mRNA expression of the full length GHR and d3GHR variant were assessed 
by real time PCR. After 24 and 72 h incubation with PEG-V, in different concentration 
(10-6-10-9M), GH secretion was assessed in three primary GH-secreting cultures. With a 
two-site immunofluorometric assay having no cross-reaction with PEG-V, GH concentra-
tions were determined.
Results: In somatotroph adenomas, detectable levels of full length GHR and the d3GHR 
variant were found in 27 of 32 (84%) and in 23 of 32 (72%) cases respectively. GHR mRNA 
levels, full length and d3GHR, in the somatotroph adenomas amounted 0.8 and 4.8% of 
the expression level in human liver. The addition of PEG-V did not increase GH secretion 
by the cultured GH-secreting pituitary adenoma cells.
Conclusion: In human somatotroph pituitary adenomas the expression of GHR mRNA is 
low and PEG-V does not increase GH secretion in vitro. There was no relationship between 
expression of GHR in the adenoma and the effect of PEG-V. Therefore, the increase in GH 
level during PEG-V treatment in acromegaly patients does not seems to be mediated 
by interference of PEG-V with an ultra-short feedback loop via GHR in the somatotroph 
adenoma, but possible via reduced feedback due to the lowered circulating IGF1 levels.
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INTroduCTIoN
Acromegaly is a rare disease that is caused, in at least 95% of cases by a benign, growth-
hormone (GH) secreting pituitary tumor [1]. More than 75% of these pituitary tumors are 
macro-adenomas, which often extent dorsally of the suprasellar region or laterally to the 
cavernous sinus [1]. The elevated levels of GH [2-4] and insulin-like growth factor 1 (IGF1) 
[5-7] seem to be the most important factors that determine reduced life expectancy, in 
this disease. By normalizing these parameters the life expectancy can return to normal 
[8]. The most effective available treatment modalities to achieve these goals are surgery 
and medical therapy. Medical therapy with somatostatin analogs (SRIF) normalizes IGF1 
and growth hormone levels in about 50% of patients [9]. Pharmacotherapy with SRIF 
analogs have greater efficacy than surgical treatment in patients with macro-adenomas. 
However, compared with pegvisomant (PEG-V) therapy, SRIF analog therapy and surgery 
have lower efficacies. Treatment with PEG-V, either as a monotherapy or in combination 
with a SRIF, is effective in more than 90% of cases. During combined treatment a reduced 
cumulative dose of PEG-V seems to be necessary to achieve a normal IGF1 [10-14].
In patients circulating GH levels increase during PEG-V treatment, but when PEG-V is 
combined with a SRIF analogs, elevations in the serum concentration of GH are lower 
than they are observed during PEG-V monotherapy [10,15]. The increase in GH during 
PEG-V could possibility be explained by a blockade of the peripheral GH receptor (GHR) 
in the liver that leads to a reduction in IGF1 thereby reducing the negative feedback 
of IGF1 on the hypothalamus and pituitary gland [10,16]. By disrupting this regulatory 
mechanism of the GH/IGF1 feedback, a potential tumor growth might occur [17,10].
Different areas in the brain, as well as the pituitary, express GHR, as assessed by 
binding studies [18] and GHR m-RNA analysis [19]. PEG-V seems to be incapable of pen-
etrating the blood brain barrier [20], making an effect of PEG-V via the central nervous 
system unlikely. However, the pituitary gland is outside the blood brain barrier, which 
means that PEG-V should be able to reach the pituitary. GH itself could influence the 
pituitary via an ultra short feedback loop as shown for thyroid stimulating hormone 
(TSH) [21]. Via a similar mechanism PEG-V blockade of the pituitary GHR could increase 
GH production further and influence tumor growth. In this study we therefore assessed 
mRNA expression of the GHR in somatotroph adenomas and the effect of PEG-V on GH 
secretion by somatotroph adenomas in vitro.
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MATerIAl ANd MeTHodS
Patients
Pituitary adenoma tissue samples were directly used for cell culture. A representative 
piece of tissue was snap frozen on dry ice and used for RNA isolation. The samples 
derived from thirty-two patients with clinically proven somatotroph adenomas and 
were obtained from surgical specimens after transsphenoidal surgery between 2009 
and 2010 at the Department of Neurosurgery, Erasmus University Medical Centre Rot-
terdam. At immunohistochemical examination all these adenomas were positive for GH. 
As a reference for GHR expression, four hepatic tissue specimens were obtained for the 
Department of Pathology Erasmus University Medical Centre Rotterdam. All patients 
gave their informed consent to use the adenoma tissue for research purposes.
Cell dispersion and cell culture
Single-cell suspensions of the pituitary adenoma tissues were prepared by enzymatic 
dissociation with dispase as described in detail previously [22]. For short-term incuba-
tion of monolayer cultures, the dissociated cells were plated in 48-well plates (Corn-
ing, Cambridge, MA) at a density of 105 cells per well in 1 ml culture medium. After 
3–4 d, the medium was refreshed and 24 to 72-h incubations without or with PEG-V 
(10-6,10-7,10-8,10-9M) were initiated in quadruplicate. At the end of the incubation, the 
medium was removed and stored at –20°C until analysis of the GH concentrations.
The cells were cultured at 37°C in a CO2 incubator with humidified air. The culture 
medium consisted of MEM supplemented with nonessential amino acids, sodium pyru-
vate (1 mmol/liter), 10% fetal calf serum, penicillin (1 x 105 U/liter), fungizone (0.5 mg/
liter), L-glutamine (2 mmol/liter), and sodium bicarbonate (2.2 g/liter, pH 7.6). Media 
and supplements were obtained from Gibco Bio-cult Europe (Invitrogen, Breda, The 
Netherlands).
Quantitative PCr
Total RNA was isolated using a commercially available kit (high pure RNA isolation kit; 
Roche, Almere, The Netherlands). cDNA synthesis and quantitative PCR using the Taqman 
Gold Nuclease assay and the ABI PRISM 7900 sequence detection system (Perkin Elmer 
Applied Biosystems, Groningen, The Netherlands) were performed as described in detail 
previously [23]. The primers and probes sequences were obtained from Sigma-Aldrich (St. 
Louis, USA). The primer sequences were as follows for GHR full length; forward: 5’-ATCT-
TTGG AATA TTTG GGCT AACA GT-3’, reverse: 5’-GGAT CGAT TCCT TTAA TCTT TGGA-3’, probe 
5’-fam-agga ttaa aatg ctga ttct gccc ccag-TAMRA-3’ and for d3GHR variant; forward: 5’-TCTT-
TGGA ATAT TTGG GCTA ACAGT-3’, reverse: 5’-AGCT ATCA TGAA TGGC TAAGATT GTG-3’, probe: 
5’-FAM-TAAA CAGC AAAG GAAG GAAA ATTA GAGGA GGTGA-TAMRA-3’. Dilution curves were 
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constructed for calculating the PCR efficiency for every primer set. Efficiency values were 
similar for GHR full length and the d3GHR variant. The estimated copy numbers were 
calculated using the comparative threshold method with efficiency correction [24].The 
detection of hypoxanthine-phosphoribosyl-transferase (hprt) mRNA served as a control 
and was used for normalization of the d3GHR and full length GHR mRNA levels. Primers 
and probes to detect hprt have been described previously [25]. To exclude contamination 
of the PCR mixtures, the reactions were also performed in the absence of cDNA template, 
in parallel with cDNA samples.
growth Hormone assay
GH concentrations were assessed by a PEG-V-insensitive two-site competitive mono-
clonal immunofluorometric assay as described before [26]. To assess PEG-V and GH in 
supernatants of the pituitary adenoma cell cultures, the assay was slightly modified. Cell 
culture medium was used as the matrix for the calibrators. All samples were analyzed in 
a single run. Inter- and intra-assay coefficients of variation were 8.7% and 6.5%.
Statistics
All data on m-RNA levels are expressed as mean ±SE or as percentage of the mean m-
RNA level of the liver. The groups were compared by Mann-Whitney test or when data 
was paired by Wilcoxon matched pairs test. The GH levels were analyzed by ANOVA for 
repeated measurements. Analysis was performed by GraphPad Prism version 5.00 for 
Windows, GraphPad Software, San Diego California USA. Statistical significance was 
accepted at P<0.05.
reSulTS
In the somatotroph adenomas, GHR full length mRNA and d3GHR were detectable 27 of 
32 (84%) and in 23 of 32 (7%) cases respectively. Full length and d3GHR mRNA expres-
sion levels were 0.036 ±0.006 and 0.018 ±0.005 (ratio/hprt), respectively (fig.1). The full 
length and d3GHR mRNA expression levels of the liver were 4.274 ±2.434 and 0.373 
±0.193 (ratio/hprt) respectively (fig.1). Compared to total GHR expression, expression of 
full length vs. d3GHR in the somatotroph adenomas was 67% vs. 33%. For the liver this 
ratio was 92% vs. 8%. mRNA expression of GHR full length in somatotroph adenomas, 
as the percentage of the liver expression amounted 0.8%. The mRNA expression of the 
d3GHR variant amounted 4.8% of the expression level detected in human liver tissue. 
The overall mRNA expression of the GHR in the somatotroph adenomas was only 1.2% 
compared to the liver expression level.
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Three somatotroph adenoma cultures were incubated for 24 h and 72 h with PEG-V 
in various concentrations (control,10-6,10-7,10-8,10-9M). After 24 h and 72 h incubation 
with PEG-V, GH secretion did not change significantly at any of the PEG-V concentrations 
tested (fig. 2). The lack of responsiveness appeared not to be related to the absence of 
GHR expression, except for one of the adenomas. Expression levels (ratio/hprt) of the 
adenomas of patients 1, 2 and 3 were 0.0120, undetectable and 0.039 for GHR full length 
and 0.0020, undetectable and 0.018 for d3GHR, respectively.
dISCuSSIoN
In the present study low mRNA expression of full length GHR and the d3GHR was found 
in 32 somatotroph pituitary adenomas. After the addition of PEG-V, no increase in GH 
concentration of supernatant was observed. Therefore, it seems very unlikely that the 
increase in GH during PEG-V treatment in humans is due to a blockade of an ultra-short 
feedback loop via GHR in the somatotroph pituitary adenomas by PEG-V.
The % of adenomas expressing GHR mRNA in our cohort of patients was comparable 
with that described by Beuschlein et al. [19]. However, they did not did not assess the 
relative mRNA expression to that of the human liver. Moreover, Kola et al. observed that 
GH-R mRNA expression levels in GH-secreting pituitary adenomas were lower compared 
those in normal pituitary [27].
A dose dependent increase in circulating GH levels during PEG-V treatment in 
acromegaly was already observed in the early clinical studies [10]. The increase in GH 
levels is probably not caused by an altered circulating halftime of GH and/or clearance 
during PEG-V treatment, but by a true increase in GH production [26]. Another possibil-
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figure 1: Comparison between mRNA expression levels of the full length GHR and the d3GHR variant, 
as determined by quantitative PCR in GH-secreting pituitary adenomas and liver tissue. All values are 
expressed as mean ± SE (Standard Error). Expression levels are normalized to the expression levels of hprt.
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ity is that PEG-V blocks an ultra-short feedback loop as was observed with TSH on the 
pituitary [21]. Until now, this hypothesis has not been evaluated. However, since the 
mRNA levels of the GHR are very low compared with liver GHR expression level [19] 
and because PEG-V did not increase GH secretion in vitro by somatotroph adenomas, 
this suggests that modification of the putative ultra-short feedback loop is very unlikely, 
in these adenomas. In other parts of the brain GHR are present as well, such as in the 
hypothalamus, [18] which could also partially explain the increase in GH levels during 
PEG-V treatment in acromegaly. However, Veldhuis and co-workers recently assessed 
PEG-V in the Cerebrospinal fluid (CSF). The uptake of GH was 1500 fold higher than that 
of PEG-V[20]. Therefore, it seems very unlikely that a direct effect via the central nervous 
system could explain the increase in GH levels during PEG-V treatment.
As indicated above, the lack of increase in GH secretion in vitro seems most likely 
explained by the low number of GHR on the somatotroph adenomas. Although not 
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figure 2: The effect of PEG-V at decreasing dose on GH secretion by cultured somatotroph adenomas. 
2A: 24 hr incubation (adenoma 1 and 2) and 2B: 72 hr incubation (adenomas 1,2 and 3). All values are 
expressed as mean ± SE (Standard Error).
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investigated, a dysfunctional GHR [28] on the somatotroph adenoma cannot be fully 
excluded. It would be of great scientific interest to assess if the apparent absence of 
an ultra-short loop feedback is also observed in primary normal human pituitary cell 
cultures.
To antagonize the GH effect in an acromegalic patient, an excess of PEG-V is required. 
The highest dose of PEG-V that we used in our in vitro experiments was more than 10 
times the amount of GH produced by the adenoma cells. Even at this highest PEG-V 
dose, no effect of PEG-V on GH secretion by the somatotroph adenomas was observed. 
Therefore, the most rational explanation for the increase in GH level during PEG-V 
treatment in acromegalic patients is the decrease in IGF1 resulting in less feedback sup-
pression at the adenoma and/or normal somatotrophs. IGF1 was previously shown to 
inhibit GH secretion by primary cultures of GH secreting pituitary adenomas, as well as 
in normal rat anterior pituitary cell cultures [29].
In conclusion, our study demonstrates that GHR mRNA levels in somatotroph adeno-
mas are low and that the addition of PEG-V is not able to increase the GH production by 
the adenomas in vitro. Therefore, the increase in GH levels during PEG-V treatment in 
acromegalic patients does not seem be mediated by interference of PEG-V with an ultra-
short feedback loop via GHR in the somatotroph adenoma, but possible via a reduced 
feedback due to the lowered circulating IGF1 levels.
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AbSTrACT
Medical treatment of acromegaly with long-acting somatostatin analogs (SRIF) and the 
GH receptor antagonist, pegvisomant (PEG-V), has made it possible to achieve normal 
serum IGF1 concentrations in a majority of patients with acromegaly. These two com-
pounds, however, impact the GH–IGF1 axis differently, which challenges the traditional 
biochemical assessment of the therapeutic response. We postulate that long-acting SRIF 
analogs in certain patients normalizes serum IGF1 levels in the presence of elevated 
GH actions in extra-hepatic tissues. This may result in persistent disease activity for 
which we propose the term extra-hepatic acromegaly. PEG-V, on the other hand, blocks 
systemic GH actions, which are not necessarily reliably reflected by serum IGF1 levels, 
and this treatment causes a further elevation of serum GH levels. Medical treatment is 
therefore difficult to monitor with the traditional biomarkers. Moreover, the different 
modes of actions of SRIF analogs and PEG-V make it attractive to use the two drugs in 
combination. We believe that it is time to challenge the existing concepts of treatment 
and monitoring of patients with acromegaly.
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INTroduCTIoN
Acromegaly is a rare disease, most often caused by a GH-producing tumor of the an-
terior pituitary [1]. Available treatment modalities to date aim at normal- izing serum 
insulin-like growth factor 1 (IGF1) levels via reduction of either GH overproduction or 
GH actions [2-5]. The obvious advantage is that the efficacy of different treatments can 
be easily compared by means of serum IGF1 measurements, as this is more practical 
than frequent GH measurements. This also applies to comparisons between the effects 
of long-acting somatostatin therapies (SRIF) and the GH receptor (GHR) antagonist, 
pegvisomant (PEG-V). This approach, however, is based on the assumption that serum 
IGF1 levels adequately and uniformly reflect disease activity. This assumption, however, 
is not necessarily valid. In this paper, we address the relationship between the GH–IGF1 
axis with a specific emphasis on the significant differences in the modes of action of 
SRIF analogs and PEG-V. In doing so, we will introduce the novel hypothetic paradigm of 
hepatic and extra-hepatic acromegaly and its potential clinical implications.
THe effeCTS of gH Are TISSue SPeCIfIC ANd CoNCeNTrATIoN 
dePeNdeNT
The physiological effects of GH versus IGF1 remain controversial. Historically, it has 
been difficult to isolate the individual effects of GH and IGF1 at the tissue level during 
physiological conditions. But the fact that GH possesses a diabetogenic or ‘anti-insulin’ 
activity [6], while IGF1 (as the name implies) is similar to insulin in its actions, clearly 
demonstrates that physiological differences exist between the actions of the two pep-
tide hormones. Below, we cite results of animal studies that address specific effects of 
GH and physiological effects of GH versus IGF1.
ANIMAl STudIeS of THe ACTIoNS of gH verSuS Igf1
Since GH is a diabetogenic molecule, it would not be predicted to be used as a pharma-
ceutical to treat type 2 diabetes. Yet its lipolytic and anti-lipogenic actions could have 
potential positive outcomes in type 2 diabetic indi- viduals. Two reports have docu-
mented beneficial effects of GH on glucose metabolism in type 2 diabetic patients [7-8].
A mouse model attempting to determine the effect of GH on diet-induced type 2 
diabetes parameters has been presented [9]. In this model, male C57BL/6J mice were 
placed on a high-fat diet to induce obesity and type 2 diabetes. During the studies, mice 
were treated with various doses of GH. Body weight and composition, fasting blood 
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glucose, insulin and IGF1 levels, glucose tolerance, liver triacylglycerol, tissue weights, 
and blood chemistries were determined. Several important findings were reported [9]. 
First, a GH dose-dependent decrease in fat and an increase in lean mass were found. 
These effects on body composition were seen at the highest two doses of GH admin-
istered, even though only the highest dose of GH resulted in elevated circulating IGF1 
levels. These results indicate that certain effects of GH are independent of circulating 
IGF1 levels. Second, the increase in lean mass was observed before the decrease in white 
adipose tissue (WAT); thus, physiological effects of GH were not observed at the same 
time points. Third, GH-induced WAT loss was specific to subcutaneous and mesenteric 
fat. This result agrees with previously published work in which subcutaneous WAT de-
pots were found to be increased in mice that lacked GH action [10-12]. Thus, these data 
further support the notion that ‘not all WAT depots are treated equally’ in terms of GH 
action and should be evaluated independently in studies with GH or other treatments.
The finding that GH can affect body composition independent of elevations in total 
serum IGF1 levels is important. However, we must point out that these GH-dependent 
changes in body composition may be due to the autocrine/paracrine actions of IGF1 
and not the direct action of GH. The importance of the autocrine or paracrine produc-
tion of IGF1 has been documented in the liver-specific IGF1 gene-deficient mouse [13].
Other mouse studies attempting to discriminate the effect of GH versus IGF1 were 
carried out nearly 20 years ago. These studies showed that animals that have high GH 
and IGF1 levels display glomerulosclerosis; however, glomerulosclerosis is not observed 
in mice with increased levels of IGF1 alone [14-15].
A continuation of these studies was carried out employing transgenic mice that ex-
press analogs of GH. For example, when a bovine (b) GH analog containing the following 
changes (L121P and E126G) is expressed in the transgenic mice, the resulting animals 
are of normal size with normal levels of IGF1; yet they display kidney glomerulosclerosis 
as severe as mice that express wild-type bGH [16]. These data suggest that GH can affect 
the kidney independent of increases in IGF1.
Additionally, diabetic kidney disease can be induced in mice using streptozotocin. 
This kidney pathology was not seen in mice that express a GHR antagonist [17-18] or 
in mice injected with PEG-V (19). Important in this latter study was the fact that kidney 
pathology was prevented by PEG-V, even in the absence of a decrease in serum IGF1 
[19]. Again, this implies that GH has a direct effect on the kidney independent of serum 
IGF1 levels.
The above data derived from mouse models of GH action suggest that GH can have 
temporal and tissue- specific effects independent of elevations of serum IGF1.
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THe relATIoNSHIP beTweeN PorTAl INSulIN ANd gH SeNSITIvITy of THe 
lIver
Human and other mammals are capable of prolonged fasting because they can recruit 
and utilize lipid stores when they exhaust readily available carbohydrates [20-22]. Pro-
longed fasting is associated with a gradual decline in hepatic IGF1 production, which 
makes teleological sense due to the insulin-like effects of IGF1. A study by Leung et al. 
suggests that GH-induced hepatic IGF1 production is regulated by portal insulin levels 
[23]. They reported that insulin promotes the translocation of the hepatic GHR to the 
surface.
When portal insulin levels are high, the liver becomes GH sensitive, regardless of the 
cause of the elevation in insulin production [23]. In addition, portal insulin also inhibits 
hepatic IGFBP1 production, which may increase the bioavailability of circulating IGF1 
[24-25].
In conclusion, high portal insulin levels increase liver GH sensitivity (via up-regulation 
of surface GHRs) and, therefore, ultimately increase liver IGF1 production with con-
comitant increases in serum IGF1 levels. In contrast, low portal insulin levels reduce the 
sensitivity of liver for GH and, therefore, reduce serum IGF1 levels.
wHy do ACroMegAly PATIeNTS HAve elevATed Igf1 levelS
Acromegaly patients have elevated IGF1 levels as a consequence of GH hypersecretion 
[1]. In addition, the elevated GH levels stimulate lipolysis and induce resistance to the 
effects of insulin on glucose metabolism in liver and muscle. The net result is a hyper-
metabolic state characterized by elevated levels of glucose, free fatty acids, and insulin 
[26-27].
The GH-induced hyperinsulinemia, in turn, is likely to further stimulate hepatic IGF1 
production and to lower IGFBP1 levels [28-29]. The importance of this effect is supported 
by the observation that prolonged fasting- induced hypoinsulinemia can completely 
normalize serum IGF1 levels in acromegaly patients [30].
In conclusion, acromegaly patients have elevated serum IGF1 levels because of the 
pathological hyperse- cretion of GH by the pituitary tumor, which is aggravated by the 
accompanying hyperinsulinemia.
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How SoMAToSTATIN ANAlogS work
Somatostatin analogs (SRIF) bind to somatostatin receptors of which subtypes 2 (sst2) 
and 5 (sst5) are the most important ones for mediating the actions of the available 
long-acting SRIF analogs [31-33]. Because of the expression of sst2 and sst5 on the 
somatotroph cells, pathological GH secretion can be inhibited by SA, which translates 
into reduced hepatic IGF1 production [31-32,34,33]. When this reduction is sufficient 
to normalize IGF1 levels, the treatment is traditionally considered adequate [31,35-37].
However, SRIF analog also binds to sst2 and sst5 receptors on the pancreatic islet, 
which will reduce glucagon and insulin secretion (38, 39). This occasionally results in a 
worsening of the glycemic control in acromegaly patients during long-term long-acting 
SRIF analog [38]. Moreover, a suppression of insulin secretion by SRIF analog also selec-
tively results in hepatic GH resistance, which itself decreases hepatic IGF1 production 
[23]. Therefore, the ensuing reduction in circulating IGF1 does not necessarily reflect GH 
activity in peripheral tissues.
A GH-independent suppressive effect of SRIF analog on serum IGF1 levels has been 
documented in two studies in humans (41, 42). Both studies involved adminis- tration 
of octreotide for 7 days during continued GH treatment in adult GH deficiency (GHD) 
patients. This resulted in a significant 16–18% reduction in serum IGF1 levels with a 
concomitant reduction in insulin levels and elevated levels of IGFBP1 [39-40].
In the context of acromegaly, it is therefore plausible that normalization of serum IGF1 
levels during long-acting SRIF analog not necessarily implies control of disease activ-
ity in peripheral tissues, i.e. a condition for which we propose the term ‘extra-hepatic 
acromegaly’ (Figure 1a). This is further supported by a recent report by Rubeck et al. 
[41]. They compared traditional and novel biomarkers and health status in patients with 
acromegaly treated with either surgery alone or SRIF analog. They reported that despite 
similar and normalized IGF1 levels, SRIF analog treatment compared with surgery alone 
was associated with less suppressed GH levels and less symptom relief. They concluded 
that this discordance may be due to specific suppression of hepatic IGF1 production by 
SRIF analogs [41].
In the absence of a convenient bioassay for disease activity in acromegaly, it is not 
easy to validate whether extra-hepatic acromegaly is a clinical entity rather than a se-
mantic issue, but it is noteworthy that impaired quality of life (QoL) has been reported in 
long-acting SRIF analog patients despite normal IGF1 levels [42].
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figure 1: (a) Effects of somatostatin analogs (SRIF) in SRIF analog-sensitive acromegalic subjects. Red 
arrows indicate inhibitory effects; green arrows indicate stimulatory effects, while thickness of arrow 
indicates level of inhibition. (b) Effects of pegvisomant in acromegalic subjects. Red arrows indicate 
inhibitory effects; green arrows indicate stimulatory effects, while thickness of arrow indicates level of 
inhibition.
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How gHr ANTAgoNISTS work
As described above, the GHR antagonist, PEG-V, competitively blocks the GHRs in all 
peripheral tissues [43-45]. Thus, the higher the endogenous GH level, the more PEG-V 
is needed to effectively block GH actions [5]. PEG-V, however, does not block all tissues 
equally effective for the actions of GH. Adipose tissue, the kidneys, and skeletal muscle 
seem to require less PEG-V to reduce GH actions compared to the liver where more PEG-
V is required in order to reduce IGF1 production [19]. In further support of this, it was 
recently reported that short-term PEG-V administration in healthy subjects can suppress 
lipolysis without affecting either circulating or local IGF1 [46].
It is therefore possible that PEG-V treatment in acromegaly is subject to tissue-specific 
differences in a dose-dependent manner. In particular, it is possible that peripheral sup-
pression of GH activity is obtained prior to normalization of hepatic IGF1 production. 
Such a condition during PEG-V therapy could be denoted ‘hepatic acromegaly’, which in 
essence is reciprocal to the putative conditions during long-acting SRIF analog (Fig. 1b). 
However, unlike extra-hepatic acromegaly, data in humans are lacking to suggest that 
hepatic acromegaly indeed does occur during PEG-V monotherapy.
leSSoNS froM dIAbeTeS TyPe I ANd II
The effects of restoring portal insulin levels on serum IGF1 have been studied in type I 
diabetes [47]. Only with portal insulin administration, did IGF1 levels increase to within 
the normal range, which resulted in a decrease in GH levels. However, diabetic patients 
on conventional insulin therapy had low IGF1 and elevated GH levels [47].
Wurzburger et al. [48] also studied GH-stimulated IGF1 levels in type 1 diabetes. The 
patients were divided into C-peptide-negative patients without residual b-cell activity 
and C-peptide-positive patients with preserved b-cell activity. A GH-induced increase in 
serum IGF1 levels was only observed in patients with remnant b-cell activity [48].
There are similarities between type I diabetes and long-acting SRIF analog-treated 
acromegalic subjects: both exhibit elevated systemic GH activity together with relative 
hepatic GH resistance due to low portal insulin levels. The difference is that type I dia-
betic subjects have low IGF1 levels, while long-acting SRIF analog-treated acromegalic 
subjects have normal or elevated IGF1 levels. There are also similarities between type 2 
diabetes and PEG-V-treated acromegalic subjects: both exhibit low systemic GH activity 
in the presence of relatively high hepatic GH sensitivity due to normal or elevated portal 
insulin levels.
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wHAT AbouT CoMbININg SrIf ANd Peg-v
Several papers have presented data on combination therapy with long-acting SRIF 
analog and PEG-V. To date, the focus in these reports has been on patients with an 
insufficient response to long-acting SRIF analog [49-50], but we believe that combina-
tion treatment may offer benefit to other patients. The strongest evidence for this is 
presented by Neggers et al. [51]. They hypothesized that weekly administration of 40 
mg PEG-V could improve QoL and metabolic parameters in acromegalic patients with 
normal age-adjusted IGF1 concentrations during long-acting SRIF analog treatment. In 
a double-blind, placebo-controlled, crossover study, 20 acromegalic subjects received 
either PEG-V or placebo for two consecutive treatment periods of 16 weeks, sepa-
rated by a wash-out period of 4 weeks. Efficacy was assessed as a significant change in 
disease-specific QoL between baseline and at the end of each treatment period. QoL 
was assessed by the acromegaly QoL questionnaire (AcroQoL) and the patient-assessed 
acromegaly symptom questionnaire (PASQ). Interestingly, the AcroQoL and AcroQol 
improved significantly after PEG-V was added. The addition of PEG-V also significantly 
improved the PASQ and the single PASQ questions dealing with perspiration, soft tissue 
swelling, and overall health status. By contrast, no significant changes in IGF1 levels 
were observed during the addition of PEG-V. As the age- dependent normal range for 
IGF1 is still relatively wide, it might be possible, however, that some patients may have 
a statistically normal IGF1 level that is in fact too high for them. Addition of weekly 
PEG-V might induce a short-lived decline of IGF1 for 2 days, which does not register if 
the blood is drawn 7 days after PEG-V administration, but the clinical effects might be 
manifested in QoL questionnaires. Thus, low-dose PEG-V treatment improved the signs 
and symptoms of ‘extra-hepatic acromegaly’ without impacting hepatic IGF1 produc-
tion consistent with our hypothesis of extra- hepatic acromegaly. It is noteworthy that 
the largest improvement in QoL was observed in patients who also responded to PEG-V 
with alleviation of fluid retention [51]. It remains to be studied whether the same favor-
able effects could be obtained by an increase in the dose of long-acting SRIF analog.
CoNCluSIoNS ANd fuTure dIreCTIoNS
SRIF analog have stood the test of time as a safe and effective treatment for acromegaly; 
however, adequate control of the disease is not always achieved. With the recent in-
troduction of PEG-V, it is now possible to obtain biochemical control of the disease in 
most patients. Thus, now is an appropriate moment for critical evaluation of the proper 
assessment of the therapeutic outcome with these two different treatment modalities. 
In particular, we postulate that circulating IGF1 is not necessarily the most reliable 
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biomarker of disease activity. SRIF analog have at least three tissue-specific effects: i) 
decreased GH secretion from the pituitary tumor, ii) decreased insulin secretion from the 
pancreas, and iii) decreased hepatic IGF1 production that may lead to a normalization 
of serum IGF1 levels despite insufficient control of disease activity in peripheral tissues. 
The combination of these effects may lead to a state of normalized serum IGF1 levels 
and residual peripheral disease activity, i.e. extra-hepatic acromegaly. Whether this is of 
clinical significance and whether it may be overcome by simply increasing the dose of 
long-acting SRIF analog merits are to be addressed in a controlled clinical trial. It would 
be obvious to compare the outcome of LA-SRIF analog in patients who are randomized 
to dosing according to either serum IGF1 levels or GH levels.
The use of PEG-V also is challenging since this treatment is accompanied by a further 
elevation in GH levels. Moreover, there is evidence to suggest that PEG-V in some cases 
may induce significant blockade of peripheral GH actions prior to blockade of the he-
patic GHRs. In this context, it is also noteworthy that the dose requirements of PEG-V 
are subject to a wide inter-individual variation. Novel biomarkers in addition to IGF1 for 
this individual variation are needed. It also remains to be determined whether assess-
ment of serum PEG-V levels would be useful. We believe that patients using combination 
therapy of SRIF analog and PEG-V should be monitored with more specific ways. This 
might include procollagen II levels or another parameter that can integrate GH actions 
on the ‘extra-hepatic’ tissues such as bone.
The fact that long-acting SRIF analog and PEG-V exert complementary suppressive 
effects on the GH–IGF1 axis makes combination therapy with the two modalities an 
interesting option. Indeed, there is evidence to suggest that combination therapy is 
superior to monotherapy with long-acting SRIF analog in terms of glucose homeostasis 
[50] and disease-specific QoL [51]. The latter observation also suggests that assessment 
of QoL could be considered as routine practice during medial therapy. Our hope is that 
the introduction of the hypothetic paradigm of extra-hepatic acromegaly will challenge 
basic scientists, clinicians, and pharmaceutical industries to design and perform studies 
that show that we are wrong, because if we are not, medical treatment of acromegalic 
patients might need a significant update. Last but not least, we believe there is a need 
for novel biomarkers (either genomic, metabolomic, proteomic, or others), which ideally 
integrate hepatic as well as peripheral disease activity.
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INTroduCTIoN
With the introduction of PEG-V, new possibilities became available for the treatment of 
acromegaly. Initially, PEG-V was used as a single agent in the treatment of acromegaly, but 
in view of its possible involvement in tumour growth [1], the high cost of this new medi-
cation and the broad use of SRIF analogs inspired investigators to assess the combined 
use of SRIF analogs and PEG-V [2]. One of these investigators, AJ van der Lely started by 
combining high dose SRIF analogs with weekly PEG-V. The first part of this thesis, chapters 
2, 3 and 4, is focused on the efficacy, safety and costs of this combination treatment in up 
to that time uncontrolled acromegalic patients during SRIF analog treatment.
The second part of this thesis, chapters 5 and 7, concentrates on QoL in long-term 
controlled acromegaly patients during long-acting SRIF analogue treatment, with or 
without PEG-V. Furthermore, this part of the thesis describes the tissue specific physiol-
ogy of the GH-IGF1 axis, which may explain the benefit from combining PEG-V and SRIF 
analogs.
Finally, in chapter 6 a possible explanation for the increase in GH levels during PEG-V 
monotherapy is studied. If a GH receptor would be present in the pituitary adenoma, 
PEG-V should be able to block these and thereby increase GH levels. A Similar ultra-short 
feedback loop is found in other pituitary hormone system as TSH.
PArT 1
effICACy of CoMbINed TreATMeNT ANd CoST reduCTIoN
Clinically, acromegaly is characterized by soft tissue enlargement, excessive skeletal 
growth and reduced life expectancy [3]. In at least 95 % of cases it is caused by excessive 
growth hormone (GH) secretion by a benign pituitary tumour. More than 75 % of these 
pituitary adenomas are macroadenomas, which often extends dorsally of the suprasel-
lar region or laterally to the cavernous sinus [3]. Depending on the size, localization of 
the pituitary adenoma and the patients’ characteristics, a treatment modality should be 
chosen.
Available treatment modalities to date aim at normalizing serum IGF1 levels via reduc-
tion of either GH overproduction or GH actions. [4-7]. The obvious advantage is that 
the efficacy of different treatments can be easily compared by means of serum IGF1 
measurements, as this is more practical than frequent GH measurements.
Over 90 % of the patients are treated by transsphenoidal surgery. Transsphenoidal 
surgery is a well-established first line treatment for microadenomas in acromegaly. In 
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patients with a microadenoma, remission can be achieved in about 80% [8] and recur-
rence is reported in 3-10% of the patients [9-12]. Long-term efficacy largely depends 
on the experience of the neurosurgeon, while GH levels at diagnosis, tumour size and 
extrasellar invasion also play a major role in this. In hospitals without highly specialized 
neurosurgeons, remission rates of less than 40 % are not uncommon in patients with 
microadenomas [13]. Compared to treatment with ,somatostatin (SRIF) analogs, that 
have an efficacy rate of 44-77% in normalising IGF1 levels, remission rates for surgery 
are within the same range (40%-80%). However, successful surgery is accompanied 
by a rapid fall in GH and IGF1 and the costs relative to long-term drug therapy (SRIF 
analog, PEG-V) are low. Despite this, after surgery, remission is reached in less than 50 
% of patients with macroadenomas, even in centres with experienced neurosurgical 
staff [3]. Generally, reported remission rates are between 20-30 % for macroadenomas 
[13]. When compared to efficacy rates of medical treatment with SRIF analog and/or 
PEG-V, surgical efficacy rates in patients with macroadenomas are unacceptably low. 
There might be one exception, which is the intrasellar macroadenoma. In this specific 
case remission rates are observed of approximately the same magnitude as with the 
microadenomas [13].
Combination treatment with SRIF analogs and PEG-V achieve normal IGF1 levels in 
more than 90% of patients [14-15]. This is clearly shown in chapter 2 and 3. These efficacy 
rates are comparable with PEG-V monotherapy [7]. However, from the observational 
registry, Acrostudytm, efficacy rates of 62% are reported [16]. In this registry the majority 
of patients were treated with PEG-V daily. Combinations of somatostatin analogs and 
dopamine agonist with PEG-V were used in 4% of patients [16]. The mean weekly dose of 
PEG-V was 106 mg in patients with a normal IGF1, and 113 mg in those with an elevated 
IGF1. The mean weekly dose in the study by van der Lely was around 130 mg, with an 
efficacy rate of >90% [7].
With an equal efficacy rate, but at a mean weekly PEG-V dose of 77 mg, long-term 
combination therapy seems to help reduce the required dose of PEG-V [14,17]. This is 
clearly shown in chapter 2 and 3, although the magnitude of the decrease in dose can 
differ greatly between patients, as observed in chapter 4.
Yearly, cost reductions of up to €65.000 can be attained. Considering that treatment 
with high-dose SRIF analogs costs between €19.000 – 25.000, depending on the coun-
try, our data indicate that in patients who need high-dose PEG-V during monotherapy, 
a significant reduction in costs can be achieved without losing efficacy in normalizing 
IGF1 levels.
The rationale behind the dose reduction in PEG-V during combined therapy with 
SRIF analogs and PEG-V is an increase of about 20% in PEG-V serum levels [18,1]. Ad-
ditional growth hormone levels decrease due to the use of SRIF analog treatment [18]. 
Thus, PEG-V, which is a competitive blocker of the growth-hormone receptor, has less 
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GH to compete with for receptor binding, which increases its pharmacological effect. 
Additionally, in experiments rodents showed that SRIF analogs decrease the number of 
growth hormone receptors expressed in the liver owing to a decrease in portal insulin 
concentration [19-21]. Finally, SRIF analogs direct inhibition of IGF1 synthesis in the liver 
[22]. These mechanisms suggest that the combined use of somatostatin analogs and 
PEG-V enables clinicians to administer PEG-V at a reduced dosage and frequency.
SAfeTy of CoMbINed TreATMeNT
The most commonly observed adverse effect of pegvisomant therapy or SRIF analog 
and PEG-V combination therapy is liver dysfunction (Chapter 2-3), which includes he-
patocellular and cholestatic liver disturbances. Cholestatic abnormalities are indicated 
by elevated levels of alkaline phosphatase and alkaline γ-glutamyltranspeptidase and 
radiological signs of biliary obstruction. These deleterious effects on liver function are 
most often related to treatment with somatostatin analogs [23]. Many patients with such 
abnormalities have asymptomatic bile stones, but active disease that requires surgery or 
endoscopic retrograde cholangiopancreatography intervention is rare [23]. During com-
bined treatment 3 patients had gallstones. The cholestatic disturbances were treated 
with cholecystectomy in two of these patients and all patients continued combination 
therapy. In the other patient the cholestatic disturbances were transient [14-15,17].
Hepatocellular disturbances are indicated by elevated levels of transaminases, which 
are probably related to the use of pegvisomant [24]. The mechanism behind the elevated 
levels of transaminases remains unclear. The prevalence of such elevations seems to be 
higher during combination treatment (11.0-15.0%) [25,14,17] than during pegvisomant 
monotherapy (5.2%) [24]. However, since our patients visited the outpatient clinic every 
6-8 weeks, and patients from the German Pegvisomant observational Study did attend 
a regular follow up, underreporting could explain the difference in prevalence. The 
elevations in transaminase levels are usually mild and transient and occur within the 
first year of treatment [14,26,15,17]. Of note, most patients who had elevated levels of 
transaminases during combination treatment continued taking pegvisomant, whereas 
many of those who had such symptoms during pegvisomant monotherapy did not 
[17]. One patient on combination treatment, who received weekly PEG-V discontinued 
treatment [2,27]. He was re-challenged with pegvisomant alone, levels of transaminases 
increased again, so PEG-V treatment was stopped [27]. In a series of four patients who 
previously had elevated levels of transaminases, this type of liver dysfunction occurred 
again when pegvisomant was reintroduced after a drug-free period of more than 4 
months [26,17]. A subgroup of patients with acromegaly, those with diabetes mellitus, 
seem to have an increased risk of developing elevated levels of transaminases [14-15,17]. 
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The average rise in transaminase levels in these patients is approximately 2.3-fold that 
in those without diabetes mellitus (DM). [14]. In some studies, however, no association 
was found between the presence of DM and elevated levels of transaminases [28,24,16]. 
The impact of DM seems to fade in the large cohort of patients [14]. A common polymor-
phism, UGT1A1*28, associated with Gilbert’s syndrome seems to be associated with the 
occurrence of elevated levels of transaminases during monotherapy PEG-V, as was male 
gender. [29]. The incidence of homozygous and heterozygous genotypes of UGT1A1*28 
in acromegalic patients was 54% [29]. Currently, no other factors are known to increase 
levels of transaminases in these patients, as transaminase levels do not seem to be 
related to the cumulative dose of pegvisomant (or to concomitant medication). Further 
studies into the cause of the elevated transaminases should be aimed at the UGT1A1*28 
polymorphism which may be correlated with efficacy parameters. The observation of 
increased risk of developing these liver enzyme disturbances in diabetes, and the need 
for a higher dose of PEG-V to normalize IGF1, could well be a clue. However, the cumula-
tive dose of PEG-V does not increase the risk of elevated transaminases.
Tumour size
Pegvisomant is unable to prevent tumour growth, but in only a few cases has clinically 
important tumour growth been reported [30,25]. In the German Pegvisomant Obser-
vation Study tumour increase was carefully and systematically reviewed in over 300 
patients. After this systematic review, only 3 patients of the 8 patients reported initially 
had a real, but minor, increase in tumour size after PEG-V was started [30]. In the other 3 
of the 8 subjects, the originally reported increase in tumour-size already started before 
the initiation of PEG-V treatment. In 2 subjects a known rebound of tumour-size was 
present after cessation of SRIF analogs [30]. During combination treatment no tumour 
size increase was observed in about 99 patients [17]. Only in the study by Jorgensen and 
co-workers was an increase in tumour size observed in one of the 11 patients studied 
[18]. Some of the patients in this study, however, received a high dose of long-acting 
octreotide (30 mg every 2 weeks) prior to study entry. There was no data on the tumour 
size increase prior to study entry and the study also consisted of a period with PEG-V 
monotherapy as well. Therefore, it is impossible to determine if the increase in tumour 
size is caused by a rebound effect after discontinuation of SRIF analogs or by continued 
growth of the adenoma which started prior to study entry. Moreover during combina-
tion treatment, in about 19% of the subjects a decrease in tumour size was observed 
[14,17].
lipodystrophy
Lipodystrophy has been described by several reports in both combined and monother-
apy with PEG-V [31-32,14]. The prevalence is low, and when lipodystrophy does occur, 
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frequent change of injection site has been shown to reverse local lipohypertrophy after 
8 months [14]. The explanation for this phenomenon is probably the local severe GH de-
ficiency due to very high tissue levels at the injection site in the presence of insulin. This 
misbalance leads to accumulation of adipose tissue around the injection sites [28,17]. In 
some patients this leads to discontinuation, in others frequent change of injection site 
reversed the local reaction.
glucose metabolism
The advantage of PEG-V treatment over SRIF analog therapy with respect to carbohy-
drate metabolism has been established in a study of healthy volunteers [33]. In this 
study, administration of PEG-V did not influence levels of fasting glucose and insulin or 
response to an oral glucose tolerance test; in contrast, octreotide augmented glucose 
levels and impaired the insulin response. Combination treatment resulted in lower fast-
ing glucose levels than were achieved with octreotide treatment alone, but no significant 
difference was observed in insulin levels [18]. In long-term studies, combination treat-
ment decreased HbA1c levels in patients with diabetes mellitus and acromegaly, despite 
reduced dose requirements for insulin or oral anti-diabetic medication [14-15,17]. This 
finding was not confirmed, however, in a study by De Marinis and co-workers [34]. It 
seems that in the hierarchy of the beneficial effects on carbohydrate metabolism, PEG-V 
as monotherapy is superior to combined treatment. However, the combination is better 
than SRIF analog monotherapy (chapter4).
In conclusion; combined treatment with SRIF analogs and PEG-V has similar efficacy 
rates as PEG-V monotherapy. However, the cumulative mean weekly dose seems to be 
significantly lower during combined treatment. This results in a cost reduction that dif-
fers between individual patients. The safety profile of the combination therapy is more 
or less comparable with PEG-V monotherapy. Although transiently elevated levels of 
transaminases seem to occur at a higher rate. On the other hand, during combined 
treatment no tumour size increase was observed and in a substantial group of patients 
tumour size decreased. Finally, the combined treatment provides the best of both worlds 
(SRIF and PEG-V) since glucose homeostasis seems to be improved when compared with 
SRIF analog monotherapy.
PArT 2
Recent improvements in the medical treatment of acromegaly has resulted in better 
biochemical disease control in virtually every acromegaly patient, as described above. 
The current consensus on the goals of treatment of acromegaly has focused on normal-
ization of IGF1 and GH and thereby a reduction in long-term morbidity and mortality 
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[35-36]. However, normalization of levels of total serum IGF1 and GH do not necessar-
ily reflect optimal quality of life (QoL) nor relief of symptoms, in acromegalic patients 
[37-41]. From the patient’s perspective an important parameter of disease control is QoL. 
To quantify the symptoms and QoL in patients with acromegaly, the Patient-Assessed 
Acromegaly Symptom Questionnaire (PASQ) [6-7] and the Acromegaly Quality of Life 
Questionnaire (AcroQoL) have been developed [42] (Table 1).
Table 1. Quality of life questionnaires
AcroQoL comprises 22 questions. Each question has five possible answers scored 1–5, with a total maximum 
score of 110 and quoted as a percentage. The score of 110 reflects the best possible QoL. The 22 questions 
are divided into two main categories: physical and psychological function. The psychological dimension is 
subdivided into appearance and personal relationships [42-44]. The AcroQoL has a good internal consistency 
(Cronbach’s > 0.7) [43].
 The PASQ is a disease-specific questionnaire, which consists of six questions scoring 0–8 and the seventh 
question addressing the overall health status, based on the other six questions, scoring 0–10 [6-7]. The first six 
questions evaluate symptoms as headache, excessive sweating, joint pain, fatigue, soft tissue swelling, and 
numbness or tingling of the extremities. The maximum score of these six questions is 48 and indicates severe 
signs and symptoms, with lower scores reflecting improved QoL.
During treatment SRIF analogs reduce portal insulin concentration and the number 
of available growth hormone receptors in the liver [21], and can directly inhibit IGF1 
production by hepatocytes [22]. These mechanisms suggest that although the liver 
becomes relatively resistant to growth hormone during somatostatin analog treatment, 
acromegalic symptoms still persist in other parts of the body. One might expect that 
treatment of this ‘extrahepatic acromegaly’ with low-dose, weekly pegvisomant would 
improve the growth-hormone-dependent signs and symptoms and the patient’s quality 
of life. [21].
In a prospective, double-blind, placebo-controlled, crossover trial QoL was assessed 
by AcroQoL and PASQ to assess the effects of the addition of a weekly low dose of pegvi-
somant in patients with acromegaly whose levels of IGF1 were within the age-adjusted 
normal limits during long-term SRIF analog therapy [26]. After 16 weeks of treatment 
with 40 mg pegvisomant weekly, the patients’ quality of life improved, as indicated 
by increases in the AcroQoL total score and the AcroQoL score’s physical dimension. 
These improvements were accompanied by a reduction in the total PASQ score and in 
improvement of perspiration, soft-tissue swelling and overall health status. Moreover, 
these symptoms; perspiration and soft-tissue swelling can also be provoked during 
overdosing GH treatment in patients with GH deficiency.
The improvements in patients’ quality of life, and signs and symptoms of acromegaly 
were not accompanied by a significant decrease in IGF1 level. Only change in body 
weight correlated with the improvement in the AcroQoL score’s physical dimension, but 
the treatment-related decrease in body weight was not significant. The pegvisomant-
related improvement in patients’ quality of life might be also explained by the mode 
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of action of somatostatin analogs. As mentioned above, somatostatin analogs reduce 
portal insulin concentration and the number of available growth hormone receptors in 
the liver, and can directly inhibit IGF1 production by hepatocytes. These mechanisms 
suggest that whereas the liver becomes relatively resistant to growth hormone during 
somatostatin analog treatment, acromegalic symptoms still persist in other parts of the 
body. One might expect that treatment of this ‘extrahepatic acromegaly’ with low-dose, 
weekly pegvisomant could improve the growth-hormone-dependent signs and symp-
toms and the patient’s quality of life. The observed improvement in quality of life with 
combination therapy calls into question the widely used step-up approach, according to 
which patients are only treated with pegvisomant if somatostatin analog monotherapy 
is not able to normalize IGF1 levels.
Although in some individuals IGF1 levels clearly decreased during PEG-V co-treat-
ment, for the whole group, IGF1 did not decrease significantly. This observation might 
be explained by an observation by Segev et al. [45], who reported that a GH receptor 
antagonist in rodents was able to block (in this case, renal) GH actions at lower concen-
trations than were necessary to decrease serum IGF1 and somatic growth. However, our 
study was powered to detect a difference in PASQ score and not designed to detect a 
difference in IGF1. Therefore, it is possible that studies in larger populations will observe 
a significant decrease.
The improvement in QoL can not be explained by a recall phenomenon of the ques-
tions. Our study assessed QoL over a 4-month period and it is internationally accepted 
that in most studies, a 2-wk period between test and retest is enough to circumvent 
the memory effect [46-47]. More intervention studies are needed to assess the value of 
QoL measurements in clinical practice. Whereas physicians would like to apply QoL mea-
surements in patients’ treatment, this is not readily realized. QoL determination is time 
consuming, and single questionnaires in a single patient cannot be interpreted. Thus, 
physicians tend to ask a few questions and call this QoL, resulting in large differences 
between different doctors. Thus, more studies evaluating the value of the addition of 
PEG-V in treatment are needed, but also a feasible tool to assess the QoL in daily medical 
practice. This is a prerequisite for the implementation of the studies described in this 
thesis every day medical practice.
In conclusion; QoL in acromegalic patients who normalized serum IGF1 concentra-
tions during long-term treatment with long-acting SRIF analogs can be significantly 
improved by the addition of a low weekly dose of PEG-V. This improvement does not 
seem to be accompanied by a decrease in serum IGF1 levels. This brings into question 
the importance of total serum IGF1 as a reliable parameter for QoL. The improvement in 
QoL after adding PEG-V, raises questions about the step-up approach in which patients 
are treated only with pegvisomant when SRIF analog monotherapy was not able to 
normalize IGF1 levels.
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New paradigm?
Available treatment modalities to date aim at normalizing serum IGF1 levels via reduc-
tion of GH action or GH overproduction [4-7]. A tangible advantage is that the efficacy 
of different treatments can be easily compared by means of serum IGF1 measurements, 
as this is more practical than time consuming, and costly, 24h GH measurements. This 
also applies to comparisons between the effects of long-acting SRIF analog therapies 
and PEG-V. This approach, however, is based on the assumption that serum IGF1 levels 
adequately and uniformly reflect disease activity. This assumption, however, is not 
necessarily valid.
Although GH regulates IGF1 and vice versa, they are not interchangeable. It is difficult 
to isolate individual effects of GH and IGF1 at the tissue level during physiological condi-
tions. But the fact that GH possesses a diabetogenic or ‘anti-insulin’ counter-regulatory 
activity [48], while IGF1 (as the name implies) is similar to insulin in its actions, clearly 
demonstrates that physiological differences exist between the actions of the two peptide 
hormones [49]. In mouse models, GH has temporal and tissue specific effects indepen-
dent of elevations of serum levels. In humans these tissue specific and without a change 
in IGF1 serum levels are hard to study. In adipose, kidney and skeletal muscle local activ-
ity of GH can be blocked with PEG-V without any change in serum IGF1 [50]. Therefore 
treatment with PEG-V monotherapy in acromegaly will lead to a blockade of peripheral 
GH action without decreasing IGF1 levels, which we could call “hepatic acromegaly”. 
In order to normalize IGF1, with PEG-V, peripheral tissues could become GH deficient. 
SRIF analogs have an opposite effect since they reduce GH and thereby IGF1. However, 
SRIFs also decrease insulin and glucagon. This can result in a worsening of glycemic 
control during long-term SRIF analog use [51]. The lower portal insulin level selectively 
results in hepatic GH resistance [21]. This resistance causes a reduction in circulating 
IGF1 [21]. IGF1 suppression by SRIF can be GH independent in human [52-53]. Therefore 
normal IGF1 levels in acromegaly during SRIF analog treatment does not imply control 
of the disease in peripheral tissues. Since SRIFs make the liver GH-resistant, but do not 
control the acromegaly in the peripheral tissues, patients still have a decreased QoL and 
their symptoms remain [26]. By combining SRIF analogs and PEG-V this extra-hepatic 
acromegaly can be treated even though IGF1 levels are normal during SRIF treatment 
[26,49]. But the necessary dose of PEG-V might have a wide inter-individual variation. 
Since GH and IGF1 levels are far from optimal endpoints in assessing this effect, novel 
biomarkers are necessary. These novel markers should not only reflect GH action in spe-
cific tissues, but should reflect GH action in all or most peripheral tissues and the liver. 
This will be a challenging quest since to date these markers are not available.
Where should we look for this “grail”? Liver, muscle, kidney and fat are the tissues to go 
for. The kind of marker should be stable over long periods. GH and cytokines seem to in-
teract on different levels. However these cytokines are highly variable and typically hard 
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to assess. There is a relationship between the GH-IGF1 system and cytokines. Both recep-
tors, GH and IGF1 use for signalling, suppressor of cytokine signalling (SOCS) proteins 
[54]. These SOCS proteins increase after stimulation of the cell by cytokines. Imbalance 
of SOCS2 activity results in excessive somatic growth stimulated by the GH/IGF1 system. 
SOCS2 regulates GH and IGF1 signalling by preventing activation of signal transducers 
and activators of transcription (STATs). For GH this is STAT5 and for IGF1 STAT3 [54]. SOCS2 
knockout mice do not have an increased GH or IGF1, although phenotypically they are 
lean giants [55]. In SOCS2 knockout mice, in which GH is overactive, insulin seems to 
enhance GH action further without IGF1 change [56]. Lastly, SOCS2 seems to play a role 
in the development of diabetes mellitus type 2 [57]. Thus, the SOCS KO mouse model 
could be a good candidate to use for future study of our concept of hepatic acromegaly 
and peripheral acromegaly. However, these mice have an altered immune response and 
are more sensitive to the actions of GH. Therefore, it is questionable if SRIFs or PEG-V will 
have any effects in SOCS2 KO mice. Concluding, a thorough examination of the tissues 
mentioned above appears the best step to take. Possibly the SOCS2 knock out can help 
in the search for a relevant biomarker, but the ideal mouse model is not available yet.
In conclusion; SRIF and PEG-V exert complementary suppressive effects on the GH-
IGF1 axis and this makes combination treatment an interesting option. This is especially 
the case, since the addition of PEG-V to SRIF controlled acromegaly patients results in 
an increased QoL. However novel biomarkers are necessary to assess disease activity 
peripherally and in the liver.
Chapter 6
Circulating serum GH levels increase during PEG-V treatment, but when PEG-V is 
combined with an SRIF analog, elevations in the serum concentration of GH are lower 
than they are observed during PEG-V monotherapy [7,18]. The increase in GH during 
PEG-V treatment could possibly be explained by its blockade of hepatic GHR leading 
to suppression of IGF1 levels and a reduction in its negative feedback effects at the 
hypothalamus and pituitary gland [7,6]. Disruption of this regulatory mechanism could 
lead to tumour growth [1,7].
Different areas in the brain, as well as the pituitary, express GHR, as assessed by binding 
studies [58] and GHR mRNA analysis [59]. PEG-V seems to be incapable of penetrating 
the blood brain barrier [60], making an effect of PEG-V via the central nervous system 
unlikely. However, the pituitary gland is outside the blood brain barrier, which means it 
is accessible to PEG-V. GH itself could influence the pituitary via an ultra-short feedback 
loop as shown for thyroid stimulating hormone (TSH) [61]. Via a similar mechanism, PEG-
V blockade of the pituitary GHR could increase GH production further and influence 
tumour growth.
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Messenger RNA expression of somatotroph adenomas were assessed as well as GH 
levels in the supernatant of primary pituitary cell cultures after the addition of PEG-V. 
Low mRNA expression of full length GHR and the d3GHR was found in 32 somatotroph 
pituitary adenomas. The addition of PEG-V in different concentrations (10-6-10-9M) dur-
ing 24 and 72 h incubation did not increase GH concentrations in the supernatant. The 
observed GH increase during PEG-V treatment in vivo could be due to GHR blockade 
in other parts of the brain, such as the hypothalamus [58]. However, Veldhuis and co-
workers recently assessed PEG-V in the cerebrospinal fluid (CSF). The uptake of GH was 
1500 fold higher than that of PEG-V [60]. Therefore, it seems very unlikely that a direct 
effect via the central nervous system could explain the increase in GH levels. The GHR 
in our somatotroph pituitary adenomas could be dysfunctional [62]. This could explain 
the lack of GH increase after the addition of PEG-V. The doses of PEG-V to assess the GH 
response in vitro was of the same magnitude as those used in acromegalic patients to 
control IGF1, more than 10 times the amount of GH produced by the adenoma cells. 
Finally, IGF1 decreases GH levels secreted by the pituitary [63], which has been observed 
by many others [64-65].
In conclusion, our study of somatotroph adenoma GHR mRNA indicates very low levels 
of expression, and that the addition of PEG-V was not able to increase GH production by 
primary adenoma cells in vitro. Therefore, the increase in GH level during PEG-V treat-
ment in acromegalic patients seems not be mediated by interference of an ultra-short 
feedback loop via GHR in the somatotroph adenoma, but rather via a reduced feedback 
due to the lowered circulating IGF1 levels.
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Summary
Acromegaly is a rare disease, but has the attention of many physicians, researchers and 
pharmaceutical companies. This could be caused by the fascination these professionals 
have for this rare disease. This fascination goes back for centuries. In the last four decades 
three new groups of medication for the treatment of acromegaly have been discovered: 
dopamine agonists, somatostatin analogs and a growth hormone antagonist. The last 
to be discovered was pegvisomant, the growth hormone receptor antagonist. Pegviso-
mant is the most effective (medical) treatment to date.
In Chapter 2 the long-term efficacy and safety of combination treatment with long- 
acting somatostatin analogs and weekly pegvisomant was reported. Efficacy of more 
than 90%, in normalizing IGF1 was observed. This is of the same magnitude as pegvi-
somant monotherapy. However, the necessary dose to control IGF1 seems to be lower. 
This results in major cost reductions. In eight of the 32 subjects examined, elevated 
transaminases occurred during combination treatment. Two other patients had liver 
enzyme disturbances, which were due to bile obstruction. Diabetic acromegaly patients 
had 5.1 times higher risk for developing liver enzyme disturbances than non-diabetics. 
However, no patient had to interrupt the combined treatment. No tumor size increase 
was observed in any patient and in 13% of the patients a decrease in pituitary tumor size 
was observed.
In Chapter 3 the long-term safety of combination treatment with long- acting 
somatostatin analogs and weekly pegvisomant was reported, following a safety warn-
ing by the Canadian Health Authorities. The safety warning relating to liver enzyme 
disturbances was based on 26 patients during combination treatment. In a cohort of 86 
patients, presented in chapter 3, 13/86 patients developed liver enzyme disturbances 
vs. 12/229 during monotherapy pegvisomant. Diabetics did not have a higher risk for 
developing liver enzyme disturbances of more than 3 times the upper limit of normal. 
Again an efficacy rate of more than 90% in normalizing IGF1 was observed. In 19% of 
patients a decrease of more than 20% in pituitary tumor size was observed.
Although in the previous chapters the efficacy of combination treatment at a lower 
mean weekly dose of pegvisomant was discussed, no direct comparison was possible.
In Chapter 4, two patients controlled with high dose pegvisomant were converted 
to combined treatment. The dose of pegvisomant was greatly reduced by 80-150 mg a 
week. This resulted in a cost reduction of between €16,000 and 40,000 annually. How-
ever, the addition of a somatostatin analog to the treatment regimen increased fasting 
glucose and glycosylated hemoglobin levels, necessitating the addition of glucose 
lowering medication.
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From the patient’s perspective, an important parameter of disease control is the qual-
ity of life. Since this is difficult to assess in day-to-day practice, physicians tend to be 
focused more on growth hormone and IGF1 serum concentrations. To date normaliza-
tion of the biochemical markers in acromegaly is facile; physicians should endeavor for 
a higher goal and start to focus more on quality of life.
In the study described in Chapter 5 a low dose of weekly pegvisomant was added to 
the treatment of acromegalics with normal IGF1 levels receiving monotherapy with soma-
tostatin analogs, to assess a change in quality of life. This was assessed in a prospective, 
investigator-initiated, double blind, placebo-controlled, crossover study. The addition of 
pegvisomant increased quality of life assessed by Acromegaly Quality of Life Questionnaire 
(AcroQoL) and Patient-Assessed Acromegaly Symptom Questionnaire. The magnitude of 
the improvement in AcroQoL was equal to the improvement which can be observed when 
naïve acromegaly patients achieve normalization of IGF1. The typical growth hormone 
related symptoms such as perspiration, soft tissue swelling, and the AcroQoL physical can 
be improved without a change in IGF1 levels. This suggests that, although IGF1 levels are 
normal, peripheral growth hormone action is still too high. Therefore, it is questionable if it 
is correct to use the step-up approach in which patients are treated only with pegvisomant 
when somatostatin analog monotherapy is unable to normalize IGF-I levels.
Pegvisomant treatment is highly effective in controlling IGF1, but during treatment 
growth hormone levels increase. The exact mechanism behind this remains unclear.
In Chapter 6 a possible mechanism for the increase in growth hormone was assessed. 
An ultra-short feedback loop via GH receptors in the anterior pituitary gland, as shown 
for another pituitary hormone thyroid stimulating hormone, could explain this. In 32 
somatotroph adenomas and 4 samples of human liver tissue after RNA extraction, 
mRNA expression of the full length growth hormone receptor (GHR) and d3GHR variant 
were assessed by real time PCR. The mRNA expression of both GHRs at the pituitary 
adenoma level is low. After 24 and 72 hours of incubation with different concentrations 
(10-6-10-9M) of pegvisomant, growth hormone secretion was assessed in three primary 
pituitary adenoma cell cultures. The addition of pegvisomant had no effect on growth 
hormone secretion by these cells.
Therefore, the increase in growth hormone levels during pegvisomant treatment in 
acromegaly patients seems not to be mediated by interference of an ultra-short feed-
back loop via GHR in the somatotroph adenoma, but rather via reduced feedback due to 
lowered circulating IGF-I levels.
Medical treatment of acromegaly with long-acting somatostatin analogs and the 
growth hormone receptor antagonist, pegvisomant, has made it possible to achieve 
normal serum IGF1 concentrations in a majority of patients with acromegaly. These two 
compounds, however, impact upon the growth hormone–IGF1 axis in different ways, 
challenging the traditional biochemical assessment of the therapeutic response.
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In Chapter 7 a new hypothesis “extra-hepatic acromegaly” is clarified with animal 
and human data. Pegvisomant monotherapy in acromegaly leads to a blockade of 
peripheral GH action without decreasing IGF1, which we could call “hepatic acromegaly”. 
Normalization of IGF1 with pegvisomant treatment could cause peripheral tissues to 
become growth hormone deficient. However, somatostatin analogs have the opposite 
effect. Somatostatin analogs reduce growth hormone and thereby IGF1. Additionally, 
they also decrease insulin and glucagon. This can result in a worsening of glycemic 
control during long-term somatostatin analog treatment. The lower portal insulin level 
selectively results in hepatic growth hormone resistance, by decreasing the number 
of growth hormone receptors in the liver. This GH resistance ensues as a result of the 
reduction in circulating IGF1. IGF1 suppression by SRIF can be growth hormone inde-
pendent in humans. Therefore, normal IGF1 levels in acromegaly during somatostatin 
analog treatment does not necessarily imply disease control in peripheral tissues. Since 
somatostatin analogs make the liver growth hormone resistant, but do not control the 
acromegaly in peripheral tissues, patients still have a decreased quality of life and con-
tinuing symptoms. This we could call extra-hepatic acromegaly. Somatostatin analogs 
and pegvisomant exert complementary suppressive effects on the growth hormone-
IGF1 axis making combination treatment an interesting option. This is especially the 
case, since the addition of pegvisomant to somatostatin analog controlled acromegaly 
patients results in an increased quality of life. However, novel biomarkers are necessary 
to assess disease activity in peripheral tissues and the liver.
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Acromegalie is een zeldzame aandoening, maar op een of andere manier zijn vele artsen, 
onderzoekers en farmaceutische bedrijven geïnteresseerd. Dit kan verklaard worden 
door de eeuwenlange fascinatie voor deze zeldzame ziekte. In de laatste 4 decennia zijn 
3 nieuwe groepen medicijnen ontdekt voor de behandeling van acromegalie, namelijk 
dopamine agonisten, somatostatine analoga en een groeihormoon antagonist. De 
meest recente ontdekking was pegvisomant, een groeihormoon receptor antagonist. 
Pegvisomant is het meest effectieve geneesmiddel op dit moment.
In hoofdstuk 2 worden de lange termijn effectiviteits- en veiligheidsgegevens van 
de combinatiebehandeling van somatostatine analoga met wekelijkse pegvisomant be-
schreven. De effectiviteit van de combinatie behandeling om het IGF1 te normaliseren 
is meer dan 90%. Dit komt overeen met de pegvisomant monotherapie, echter is de 
dosis om dit te bereiken lager. Het gevolg hiervan is dat combinatietherapie goedkoper 
is dan monotherapie pegvisomant. In acht van de 32 acromegalie patiënten werden 
verhoogde transaminasen gevonden tijdens combinatiebehandeling. Twee andere 
patiënten hadden cholestatische leverenzym afwijkingen. Patiënten met diabetes mel-
litus en acromegalie hadden een 5.1 hoger risico op het ontwikkelen van leverenzym-
stoornissen. Ondanks de leverenzymstoornissen heeft niemand de therapie hoeven te 
onderbreken. In geen van de patiënten werd tumorgroei van het hypofyse adenoom 
gezien, maar in 13% van de patiënten werd afname van het tumorvolume gezien.
In hoofdstuk 3 worden de lange termijn veiligheidsgegevens van de combinatie 
behandeling van somatostatine analoga met wekelijkse pegvisomant beschreven naar 
aanleiding van een veiligheidswaarschuwing van de Canadese gezondheidsautoritei-
ten. De waarschuwing was gebaseerd op een studie van 26 patiënten waarin een deel 
leverenzymstoornissen ontwikkelden. In een groep van 86 patiënten, welke beschreven 
worden in hoofdstuk 3, ontwikkelden 13 patiënten leverenzymstoornissen. Tijdens mo-
notherapie pegvisomant waren dat 12 van de 229 patiënten. Diabetici met acromegalie 
hadden nu geen hoger risico meer op het ontwikkelen van leverenzymstoornissen van 
meer dan 3 maal de boven limiet. De effectiviteit om IGF1 te normaliseren was wederom 
meer dan 90%. Tumorvolume afname, van meer dan 20%, werd in meer dan 19% van de 
patiënten gevonden.
Ondanks dat in de voorgaande hoofdstukken beschreven wordt dat de combina-
tiebehandeling net zo effectief is als de monotherapie pegvisomant, alleen met een 
gemiddeld lagere wekelijkse dosis, is er geen direct vergelijk tussen monotherapie 
pegvisomant en combinatie therapie mogelijk.
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In hoofdstuk 4, twee patiënten die normale IGF1 waarden hadden met hoge dosis 
pegvisomant monotherapie werden geconverteerd naar combinatietherapie. De dosis 
reductie die behaald werd, verschilde enorm van 80-150 mg per week tussen beide 
patiënten. Dit levert een kostenbesparing op van €16.000 en €40.000 jaarlijks. Echter de 
toevoeging van somatostatine analoog leidde tot een verhoogde nuchtere glucose en 
HbA1c. Door glucos verlagende geneesmiddel verbeterden deze waarden weer.
Vanuit het perspectief van de patiënt gezien is de kwaliteit van leven misschien wel 
de meest belangrijke parameter. Echter is dit moeilijk meetbaar in de dagelijkse praktijk, 
misschien dat daarom de meeste artsen zich met name richten op IGF1 en groeihor-
moon. Tegenwoordig is het normaliseren van de biochemische waarden in het plasma 
geen probleem. Daarom zouden artsen naar een nieuwe uitdaging moeten zoeken 
namelijk kwaliteit van leven.
In hoofdstuk 5 werd er aan de behandeling van acromegalie patiënten die met soma-
tostatine analoga normale IGF1 waarden hadden, een wekelijks lage dosis pegvisomant 
toegevoegd om te bestuderen of de kwaliteit van leven zou toenemen. Dit werd in 
een “prospective, investigator-initiated, double blind, placebo-controlled, crossover” 
studie verricht. Door de toevoeging van pegvisomant nam de kwaliteit van leven toe, 
welke werd gemeten met de Acromegaly Quality of Life Questionnaire (AcroQoL) en 
de Patient-Assessed Acromegaly Symptom Questionnaire. De toename in kwaliteit van 
leven was gelijk aan de toename die men kan waarnemen als een acromegalie patiënt 
van verhoogde IGF1 daalt naar een normale waarde. De typische groeihormoon ge-
relateerde symptomen zoals zweten, weke delen zwelling en de fysieke dimensie van 
de AcroQoL verbeterde, zonder dat het IGF1 daalde. Dit suggereert, dat er ondanks de 
normale IGF1 waarden in perifere weefsel nog steeds een overschot aan groeihormoon 
te zien is. Het is daarom de vraag of combinatie therapie gereserveerd moet zijn voor die 
patiënten die een verhoogd IGF1 hebben.
Pegvisomant behandeling is erg effectief in het normaliseren van IGF1, maar dit leidt 
tot toename in groeihormoon waarden. De verklaring hiervoor is onduidelijk. In hoofd-
stuk 6 wordt een mogelijk mechanisme voor de toename in groeihormoon die tijdens 
de behandeling met pegvisomant optreedt onderzocht. Een mogelijke verklaring zou 
een ultra-short feedback loop via de groeihormoon receptoren op de hypofyse kunnen 
zijn. Bij TSH is een soortgelijk systeem bekend. In 32 somatotrophe hypofyse adenomen 
en 4 stukjes leverweefsel werd er na RNA extractie, mRNA gemeten voor groeihormoon 
receptor (GHR) en de GHR variant door middel van een real time PCR. De mRNA expressie 
van beide hypofyse GHRs was laag. Na een incubatie van 24 en 72 uur met pegvisomant, 
in oplopende concentraties (10-6-10-9M), werd de groeihormoon concentratie gemeten 
in drie hypofyse adenomen. De toevoeging van pegvisomant leidde niet tot een toe-
name van groeihormoon secretie in de hypofyse adenomen media.
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Daarom is de toename van groeihormoon spiegels, gedurende pegvisomant therapie 
niet te verklaren door een ultra-short feedback loop, maar door de daling van het IGF1 
in het serum van patiënten.
Behandeling van acromegalie met somatostatine analoga en een groeihormoon 
receptor antagonist, pegvisomant, heeft het eenvoudig gemaakt om normale IGF1 
waarden te bereiken in de meerderheid van de acromegalie patiënten. Toch hebben 
deze beide middelen een totaal verschillend effect op de groeihormoon-IGF1 as. Dit 
heeft invloed op de wijzen waarop er naar de bekende biochemische parameters wordt 
gekeken.
In hoofdstuk 7 wordt een nieuwe hypothese “extra hepatische acromegalie” beschre-
ven. Deze hypothese wordt onderbouwd door gegevens die afkomstig zijn uit onder-
zoek in dier en mensen. De behandeling met alleen pegvisomant leidt in eerste instantie 
tot een blokkade van de perifere groeihormoon receptoren zonder een verlaging van 
het serum IGF1. Dit noemen we “hepatische acromegalie”. Om met pegvisomant een 
verlaging van het IGF1 te bereiken zal de dosis zo hoog zijn dat de perifere weefsels 
waarschijnlijk groeihormoon deficiënt worden. Bij somatostatine analoga is dat precies 
andersom. Somatostatine analoga verlagen groeihormoon en daardoor IGF1. Daar 
bovenop verlagen ze insuline en glucagon. Dit leidt op de langere termijn tot een 
verslechtering van de glucose homeostase, bij het gebruik van somatostatine analoga. 
De lagere concentratie insuline in de poortader leidt tot een afname van groeihormoon 
receptoren op de lever, wat op zijn beurt weer leidt tot een afname van IGF1 concentra-
tie. Maar somatostatine analoga kunnen ook direct de productie van IGF1 door de lever 
verminderen. Daarom is een normaal IGF1 bij acromegalie patiënten die behandeld 
worden met een somatostatine analoog geen garantie dat het groeihormoon ook nor-
maal is. Omdat de somatostatine analoga de lever groeihormoon resistent maken, maar 
de perifere weefsels nog steeds te veel groeihormoon laten zien. Dit noemen we “extra 
hepatische acromegalie”. Deze extra hepatische acromegalie leidt tot symptomen en 
een afgenomen kwaliteit van leven bij acromegalie patiënten. Kortom pegvisomant en 
somatostatine analoga hebben in zekere zin een tegengestelde werking op de groeihor-
moon-IGF1 as en dit maakt een combinatie van beide middelen erg aantrekkelijk. Zeker 
omdat de toevoeging van pegvisomant aan somatostatine analoga in “gecontroleerde” 
patiënten een toename in kwaliteit van leven gaf. Maar in de toekomst moet er gezocht 
worden naar betere bio-markers voor ziekte activiteit op perifeer en lever niveau.
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List of abbreviations
AcroQoL Acromegaly quality of life questionnaire
ALS Acid-labile-subunit
ALT Alanine aminotransferase
AST Aminotransaminase
DM Diabetes mellitus
EKG Electrocardiography
GH Growth hormone
GHR Growth hormone receptor
GHRH GH-releasing hormone
GHS-RIa Ghrelin secretagogue receptor type Ia
GNAS Guanine nucleotide-binding protein
HbA1c Glycosylated hemoglobin
IGF1 Insulin-like growth factor 1
IGF1 BP3 IGF1 binding protein 3
INN Glibenclamide
LAN Lanreotide autosolution
LFT Liver function tests
MRCP Magnetic resonance cholangiopancreatography
MRI Magnetic Resonance Imaging
MT Metformin
N/A Not applicable
OD Once daily
OW Once weekly
PASQ Patient-Assessed Acromegaly Symptom Questionnaire
PEG-V Pegvisomant
QoL Quality of life
RT Radiotherapy
SD Standard deviation
SMR Standardized mortality rate
SOCS Suppressor of cytokine signalling
SOM230 Pasireotide
SRIF Somatostatin
SST Somatostatin receptor
STAT Signal transducers and activators of transcription
TC Total cholesterol
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TD Twice weekly
TLET Transient elevated liver enzyme tests
TrD Trice daily
TSH Thyroid stimulating hormone
TSS Transsphenoidal surgery
TW Twice weekly
ULN Upper limit of normal
WAT White adipose tissue
WKS Weeks
YRS Years
γ-GT γ-Glutamyltranspeptidase
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